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ABSTRACT 
 
Importance: Different ART treatments to HIV patients has been shown to be effective in 
improving a variety of disease outcomes, including CD-4 cell count improvements and 
viral suppressions. In addition to these improvements, investigators are also interested to 
evaluate the association between ART treatments and the body habitus changes of the 
HIV patients. It is unclear that which body habitus change outcomes are more greatly 
associated with what type of ART treatments and how those effects could vary depending 
on context and sample characteristics. 
Objective: To obtain overall effect sizes for the body habitus change outcome variables 
(weight, body mass index, trunk fat, limb fat and lipid parameters) and explain the 
variability among different ART treatments/interventions (NRTI, NNRTI, PI and 
combination HAART medicines) considering all treatments clustered within the current 
literatures using multilevel approach for meta-analysis.  
Data Sources: Five electronic databases (PubMed, Scopus, CINAHL, PYCHINFO and 
Cochrane Controlled Trials register) were searched starting on July 6, 2015 using a 
comprehensive Boolean Search Strategy.  
Study Selection: Studies were included if pre-and post- intervention measurements of 
body habitus changes were reported and NRTI, NNRTI, PI, and combination HAART 
medicines  LPV/r vs ABC/3TC + LPV/r;  LPV/r +ZDV/3TC vs LPV/r NVP; PI compared 
alone or, in combination with other ARTs and NNRTI compared alone or, in combination 
with other ARTs were used as treatments to HIV patients. Data from 20 studies (N = 376) 
were included.  
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Data Extraction and Synthesis: Two independent researchers identified studies that met 
the inclusion criteria and coded methodological, participant, and treatment characteristics 
using a pilot tested structured coding form. Inter-rater agreement was evaluated using 
Cohen’s kappa coefficient statistic and effect size was calculated as standardized mean 
difference as all outcome variables were continuous.  
Main Outcomes and Measures: Weighted mean effect size under random-effects 
assumption were obtained and modeled after pooling the individual standardized mean 
differences for each study on the five-body habitus change outcomes. 
Results: There were significant beneficial effects of the LPV/r combination category on 
weight and BMI [d+ = 0.44, 95% CI (0.18 to 0.71)]; [d+ = 0.94, 95% CI (0.53 to 1.3)] 
respectively. PI combination category has beneficial effect [d+ = 0.44, 95% CI (0.2601 to 
0.6311)] for limb fat. Level of HDL significantly increased in all three combination 
categories but more in favor of NNRTI combination category with large impact [d+ = 
0.85, 95% CI (0.54 to 1.15)], p-value of <0.0001. Multilevel analysis results inferred that 
estimates for HDL were statistically significantly different in three combination HAART 
treatment categories (i.e., LPV/r, PI and NNRTI combined HAART categories) with p= 
<0.0001, p=0.01 and p= <0.0001 respectively. Estimates for LDL were significantly 
different in NNRTI alone, LPV/r and NNRTI combined HAART categories. For trunk 
and limb-fat, variations were statistically significantly different between PI alone and 
NNRTI combined HAART, with corresponding p=<0.0001. Moderation analysis 
indicated that, level of LDL decreases by 0.004 units when length of intervention or, 
week increases. Limb fat increases by 0.06 units as more recent the publication is. HDL, 
LDL and TG decreases by 0.06, 0.005 and 0.07 units due to advancement of research. 
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Level of HDL and LDL decreases 0.006 and 0.01 units as number of female patients 
increases in the sample, meaning that, chances of increased HDL and LDL level is less in 
large female patients. Level of blood cholesterol and TG decreases 0.17 and 0.07 units 
due to the aging process. Proportion of white population has significant moderation effect 
on trunk fat, limb fat, cholesterol with no significant effects on weight, BMI, LDL, HDL 
and TG and methodological quality modified only limb fat. Trunk fat, limb fat and 
cholesterol increases 0.64, 0.73 and 0.50 units when proportion of white population 
increases. Methodological quality (MQ) score has moderated limb fat by 0.18 units 
indicating that due to good quality research/ high quality score, limb fat is increasing for 
the betterment of body balance.  
Conclusions and Relevance: LPV/r combined HAART is more effective with moderate 
increase of weight and BMI. PI combined HAART has significant impact on limb fat 
improvement which could be used to maintain body proportion in HIV patients as limb 
fat loss is a major concern. NNRTI combined treatment category showed large impact on 
HDL which might be prescribed as HDL reduces cardiovascular risk.
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INTRODUCTION 
 
Global Facts on HIV 
 
Human Immunodeficiency Virus (HIV) infection is a slow progressive infectious 
health condition that weakens human immune system. Approximately 36.9 million people 
are now living with HIV worldwide. The Centers for Disease Control and Prevention 
(CDC) report stated that 1.2 million people are living with HIV in the United States. 
Chances of new HIV infection remains static but the number of people living with HIV has 
increased over the past decades since the epidemic began. The majority of new HIV 
infected populations are men having sex with men (MSM), accounting for 78% in 2010. 
The prevalence of new HIV infections among women was reduced 21% from 2008 to 2010. 
Racial context reflects that HIV is more likely within African Americans, who made up 
44% of new HIV infections in 2010 (1). HIV infection is not curable; however, effective 
treatment with HIV-medications can suppress viral replication and increase CD4 cell 
counts, which reduces HIV-associated mortality, morbidity and hospitalizations with 
subsequent improvements in health quality. 
 
FDA approved HIV-medicines with their mode of action  
 
UNAIDS 2014 report regarding the accessibility of antiretroviral therapy (ART) 
highlighted that 76% of HIV infected populations undergo ART globally to reduce 
chances of spreading HIV to their sexual partners (2). The Food and Drug Administration 
(FDA) has classified ART into eight categories, including nucleoside reverse-
transcriptase inhibitors (NRTIs), non-nucleoside reverse-transcriptase inhibitors 
(NNRTIs), protease inhibitors (PIs), combination forms of ART, fusion inhibitors, 
pharmacokinetic enhancers, entry inhibitors, and integrase inhibitors with their subclasses 
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(3). For this study, we considered only NRTIs, NNRTIs, PIs and combination of HAART 
following FDA provided classifications those are made up of two or more medicines 
from one or, more HIV medicine classes such as two NRTIs, three NRTIs, two NRTIs 
plus one NNRTI, two NNRTIs plus one PI, NRTI plus NNRTI plus PI and Ritonavir 
boosted Lopinavir (LPV/r) considering widely prescribed HIV medicines by the 
practitioners to treat HIV patients. 
HIV-medicines vary in their mode of action to minimize chances of viral 
replication. Nucleoside reverse transcriptase inhibitor (NRTI) inhibits viral reverse 
transcriptase by targeting RNA dependent DNA polymerase chains. Non-nucleoside 
reverse transcriptase inhibitor (NNRTI) inhibits the reverse transcriptase without 
intracellular phosphorylation. In addition, protease inhibitor (PI) binds with proteins, 
inhibits structural protein formation, and prevents the spread of viral infection (4). 
Healthcare providers use combination of any three types of ART or, HAART as standard 
of care treatment to combat against HIV-infection (5 -6).  There is no known explanation 
for HAART’s mode of action. 
 
Immunological Response  
 
Immunologic and virologic responses may vary from one study to another due to 
the selection of different ARTs by the healthcare providers and there is a lack of written 
protocol/direction selecting medicines according to stages of HIV. One study examined 
adult antiretroviral naïve HIV patients who received HAART containing protease 
inhibitors with a median follow up of 18 months. Researchers did not find significant 
viral and immunological cell differences before and after HAART intervention (7). A 
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multicenter randomized clinical trial compared two subclasses of NRTIs along with 
NNRTI (emtricitabine plus didanosine and efavirenz vs. stavudine plus didanosine and 
efavirenz). At week 24, mean CD-4 cell count increased 156 cells/microliters for the 
emtricitabine group vs 119 cells/microliter for the stavudine group (39). To determine the 
strength of the association between the degree of the effects of HAART, one study 
conducted a meta regression analysis to assess changes in CD4 cells, viral RNA and 
progression of AIDS as outcome measures. The result explained no significant changes 
for CD-cell counts and viral load considering 24, 48 and 96 weeks as treatment time 
points along with no significant relationship between CD4 cell count changes and 
progression to AIDS or death (61). Above scientific evidence provided information on 
immunologic response at varying time points due to different antiviral treatments. Further 
research is needed addressing time frame for each antiviral treatment. 
 
Defining Body Habitus Change 
 
The benefits of antiretroviral therapy require life-long commitment, which causes 
varying degrees of bodily changes having both positive and negative effects. In 1999, 
researchers used the term “Body Habitus Abnormalities” to assess anthropometric and 
metabolic changes in HIV patients due to HAART in a Multicenter AIDS Cohort Study, 
where they collected data based on the Third National Health and Nutritional 
Examination Survey and reported on body habitus alteration/change (8). Metabolic and 
anthropometric parameters usually started to change abnormally within 2 years of 
HAART introduction, causing imbalance in lipid profile and site-specific alteration in 
body fat, resulting in subcutaneous fat loss from limbs, buttocks, face and fat deposition 
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in the intra-abdominal region or trunk with a clinical evidence in 20-35% of HIV-infected 
patients (6, 9-12). This imbalance of body constituents is associated with metabolic 
instability leading to hyperlipidemia and truncal or central fat accumulation that causes 
central obesity (13-14). Recent studies provided evidence that, obesity is progressing as 
an epidemic in HIV infected patients (62-64) and increasing more rapidly due to the use 
of new forms of antiviral therapies (65).  Patients living with HIV infection along with 
increased body mass index due to obesity are more vulnerable towards health-related 
risks and may cause rapid abnormal change in the body habitus due to having two disease 
conditions together.  
 Research teams used models to visualize the actual mechanism of body fat/body 
habitus changes. Pro-inflammatory cytokines such as tumor necrosis factor alfa acts as a 
mediator in the pathogenesis of body fat changes caused by viral infection and the 
development of a persistent inflammatory state (15). In addition, the action of viral 
proteins with paracrine and endocrine actions on adipose tissue alters adipose 
differentiation and function. As adipose tissue receives hormonal and neuronal signals, 
subcutaneous and visceral parts of human body differ functionally, metabolically and 
genetically due to the adipocyte dysfunction which is responsible for developing chronic 
conditions and severity in body habitus alterations (4, 15-16).  
 Body fat changes due to HIV infection are also associated with length of 
intervention period considering different antiviral treatments as interventions, type of 
treatments as physicians prescribe different HIV medicines such as ART alone or in 
combination, and patient demographic characteristics such as age, sex and ethnicity. One 
prospective cohort study aimed to assess body fat changes in anti-retroviral naïve HIV-
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infected adults who received HAART including two NRTIs plus at least one PI with 18 
months follow up period and found that the chances of central obesity is 7.7 per 100 
patients in one year. (7). To measure limb fat, trunk fat and metabolic features, a 
multicenter randomized study considered combination HIV medicines comparing 
ritonavir-boosted lopinavir plus zidovudine/lamivudine (ZDV/3TC/LPV/r) with ritonavir-
boosted lopinavir plus nevirapine (NVP/LPV/r) in HIV treatment naïve patients. Data 
analysis explain that, trunk fat increased in both treatment groups but limb fat increased 
in ritonavir-boosted lopinavir plus nevirapin (NVP/LPV/r) group and decreased in the 
other group (50). An observational study included 74 HIV-infected patients with a 
follow-up period of 24 months, where subjects divided into NNRTI and PI treatment 
groups by targeting weight, BMI and percentages of body fat to understand degrees of 
body habitus changes. Results from the study reveal that body weight and BMI increased 
significantly in PI group at 12 months with no change in NNRTI group. Total body fat 
decreased more than 20% comprising 16% patients on PI treatment group and 18% on 
NNRTI group concluding that body fat changes were minor and more common on PI 
(17). A prospective observational research study assessed ethnicity and gender 
differences in HIV patients receiving antiviral therapy with imbalance in limb and trunk 
fat or, lipodystrophy. Results section suggested that, white HIV male patient loss 
peripheral fat and gained central or, trunk fat, on the other hand, black females were more 
prone to lipodystrophy. Sex comparison showed that, female HIV patients gained central 
fat and males reported loss of limb fat (66). Researchers investigated association in body 
habitus changes with treatment length. Gender and ethnic difference only point out body 
fat constituents but not metabolic factors and anthropometrics targeting body mass index 
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and weight in HIV patients. In addition, to our knowledge no study considered individual 
age as risk factor which needs to be addressed very carefully as aging is an important 
natural process which can lead to fatal health conditions. 
Assessment Techniques 
 
Dual-energy x-ray absorptiometry (DEXA), computed tomography (CT), 
magnetic resonance imaging (MRI) and ultrasonography (USG) are different techniques 
used to measure body fat in general. DEXA and CT scans are the gold standard methods 
to measure body fat (18). DEXA imaging is feasible and used in HIV clinics for the 
assessment of total fat, trunk fat and limb fat in kilograms, while CT scan method used to 
evaluate visceral, subcutaneous and total abdominal fat in square centimeters. Height, 
weight, waist circumference and body mass index may provide additional information as 
recent observational studies documented on nutritional alteration due to ART in HIV 
patients resulting weight gain which might act as stimulating factor enhancing 
cardiovascular risk (19-20). 
Significance/Rationale 
 
The current evidence points out that investigators are not only focusing on CD-4 
cell count improvements and viral suppressions, but also trying to minimize abnormal 
body composition changes such as changes in weight, body mass index, body fat and 
lipid profile those can increase the risk of cardiovascular diseases due to different ART 
use. There are controversies about the clinical practice associated with HIV-medicine 
selection among health care providers along with the prevalence of body habitus 
abnormalities. Facts related to body habitus change targeting weight, body mass index, 
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body fat specially trunk and limb fat, and lipid parameters need to be addressed carefully 
for individual ART or ART alone and different combinations of ART or HAART.  
 Abnormal fat deposition is not associated with effect of ART alone but examiners also 
established the relation of trunk fat accumulation with the use of some PIs and limb fat 
loss with the use of NRTI (21-24). However, combination form of HIV medicines or 
HAART has shown dramatic immunological cell improvement than ART alone in HIV 
patients which also leading to abnormal body fat changes along with metabolic 
abnormalities in parallel way. Previous published direct and indirect meta-analysis 
explained the effects of HIV-medicines comparing NNRTI based HAART versus PI 
based HAART considering viral suppression, death or disease progression and 
withdrawals as outcomes to measure difference before and after treatment intervention in 
HIV-patients. Direct data analysis suggested that NNRTI based HAART is more 
effective than PI based HAART for viral suppression with no difference in disease 
progression for both treatment groups (25). Besides, a systematic review investigated the 
role of efavirenz (subclass of NNRTI) plus NRTI and efavirenz plus PI on body habitus 
abnormalities to measure body fats (limb-fat, trunk-fat, visceral, sub-cutaneous and total 
body fat) along with BMI and weight, where they included nine potential studies (26). In 
five non-comparative clinical trials, body fat alteration was very low while weight gain 
was significantly high when patients treated with efavirenz composed of non-thymidine 
analogues following 144 weeks of treatment. In addition, limb fat gain was higher in non-
thymidine analogue than thymidine analogue treated patients. In four comparative trials, 
limb fat increased in efavirenz treated group along with trunk fat increase in both 
efavirenz and PI treated groups.  
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 No proven HIV medicines used by the health care providers those could reduce the 
chance of body habitus abnormalities. The prevalence of excess trunk fat accumulation 
and loss of limb fat have shown to be significantly associated with disproportionate body 
fat relation in HIV patients after antiviral treatment. Evidence based research on 
abnormal fat deposition with weight gain along with obesity prevalence in HIV patients 
directed us to further investigate on weight, body mass index, body fat constituents and 
lipid profiles, considering all as an interlinked condition targeting HIV patients receiving 
antiviral medications. No previous meta-analysis has conducted considering body fat 
change or, body habitus change. With the urge to intervene more on impacts of HIV 
medicines on body habitus change this meta-analytic research explored degrees of body 
habitus changes targeting NRTIs, NNRTIs, PIs and combined forms of HAART as 
different treatment intervention options in HIV-infected patients and how those effects 
could vary depending on context and sample characteristics. We will answer what works 
best, for who and under what circumstances. In addition, this research will direct health 
care providers to select appropriate HIV medicine for patients maintaining body balance 
along with minimizing chances of cardiovascular risks. 
Research Purpose 
 
The purpose of this study was to evaluate the effects of different ART treatments on body 
habitus/ body composition among HIV positive patients-meta analyzing the scientific 
evidence. 
Research Objectives/Aims 
 
1. To obtain overall effect sizes of different ART treatments on- 
 Weight, body mass index, trunk fat and limb fat as primary outcome variables. 
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 Lipid parameters such as LDL, HDL, Total cholesterol and Triglyceride as 
secondary outcome variables. 
2. To explore variability among different ART treatments/interventions considering all 
treatments clustered within the studies using multilevel approach for meta-analysis. 
3. To explain variability and heterogeneity of different ART treatments in all outcome 
variables along with moderator analysis using study, treatment, and sample 
characteristics. 
 We hypothesized that, first, different ART treatment interventions will have 
impacts/effects, (considering Becker’s d equation to calculate effect sizes considering 
post treatment mean value minus pre-treatment mean value divided by standard deviation 
of the pre-estimated value for specific outcome) on each outcome variable favoring ART 
medicines as research hypothesis (d≠0) and ART medications on body habitus change 
has no effects as null hypothesis (d=0). Second, the studies will illustrate significant 
variability based on the Q statistics (Q is calculated as the weighted sum of the squared 
differences between individual study effects and a pooled effect across studies) and the I2 
index (I2 statistics describe the percentage of variation across studies due to variability). 
Third, for multilevel approach, our research hypothesis is that, different ART treatments 
will be statistically significantly different (χ² statistics, Q) from each other indicating p< 
0.05 for individual outcome. Fourth, multilevel model will explain the amount of 
significant heterogeneity by treatment and will explain the degree of variability (using Q 
as unexplained residual variance and I2 as index of unexplained variance) of different 
effect sizes by treatment irrespectively when we include different moderators into our 
model. 
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METHODOLOGY 
 
Systematic Search Procedure 
 
We searched five electronic databases (PubMed, Scopus, CINAHL, PYCHINFO 
and Cochrane Controlled Trials register) from July 6 to September 8, 2015. With the 
assistance of an expert librarian in a Public University library, we used specific key 
words such as “Clinical trial”, “HIV”, “Anti-Retroviral Agents", “Body Mass Index”, 
“Body fat” with medical subject headings. Detail information regarding “Boolean Search 
Terms” provided in appendix-1. A hand search of references from included studies was 
conducted to identify any missing study along with the citations published on Journals of 
AIDS, Current HIV Research.  
Identification Criteria 
 
To identify unique studies eligible for our study, we selected papers based on their 
abstract and full-text if available. Studies were included based on the pre-defined criteria: 
 Population of interest: HIV-infected patients 16 years or older with no 
previous history of anti-retroviral exposure.  
 Interventions: Studies those had pre-post intervention measurements. Stated 
following treatments as interventions- Nucleoside Reverse Transcriptase 
Inhibitor (NRTIs) or, Non-Nucleoside Reverse Transcriptase Inhibitor 
(NNRTIs) or, Protease Inhibitor (PIs) or, Combination of Antiretroviral 
Therapy (HAART) following FDA-Approved HIV-medicines (two NRTIs, 
three NRTIs, two NRTIs plus one NNRTI (Atripla), two NNRTIs plus one PI, 
NRTI plus NNRTI, NNRTI plus PI and Ritonavir boosted Lopinavir (LPV/r) 
or, Kaletra).  
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 Comparisons: Compared combined ART such as LPV/r plus NRTI vs NNRTI 
plus LPV/r or, LPV/r plus other combined ART vs LPV/r alone or, 
comparisons between PI plus NRTI vs PI plus NNRTI vs NRTI plus NNRTI 
or, NRTI vs NNRTI vs PI or, comparisons in between subclasses of NRTI, 
NNNRTI or PI. 
 Outcomes: Body habitus change considering weight, body mass index, trunk 
fat and limb fat as primary outcomes considering DEXA technique as 
benchmark to measure trunk and limb fat; and lipid parameters such as LDL, 
HDL, Cholesterol and Triglyceride as secondary outcomes. 
This research excluded studies if assessed on HIV-negative individuals, children, 
adolescent population and pregnant women. Studies were excluded those stated on 
patients taking medication for hypertension and diabetes mellitus, those could act as 
potential confounding variables. 
Quality Assessment 
 
Two independent researchers (NH and YC) provided decisions with appropriate 
justifications for final study selection process based on the selection criteria and based on 
the screening process of title, abstract and full manuscript. Total twenty unique trials 
were included for this meta-analysis Figure-1, representing the PRISMA flow diagram of 
the final study selection process. A comprehensive coding form and manual was created 
by research team consist of HIV researcher, biostatistician and a physician. The coding 
form includes approximately 200 variables for each study. Structured coding form was 
pilot tested by (NH and MC) and was reviewed by third expert (TBHM). Content coding 
form (provided in appendix 2) included information based on study information; 
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demographic characteristics; ethnicity; anthropometrics such as height, weight, waist 
circumference, waist-hip ratio, total body fat %, trunk fat, limb fat; metabolic parameters; 
lipid parameters such as LDL, HDL, cholesterol, triglyceride; route of HIV transmission: 
homosexual, heterosexual, blood contamination; stages of HIV infection following CDC 
stages; number of patients at the beginning and end of trial along with specific criteria for 
lost follow up; intervention characteristics; methodological quality; type of HIV-
medicines used as treatment interventions and risk of bias Table-1 explained information 
on study characteristics, number of patients, duration, demographics and type of ART 
used as ART treatments along with comparison groups of twenty included literatures. 
Two independent researchers (NH and YC) collected data separately. After data 
collection inconsistencies were resolved by an expert professional (TBHM) 
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DATASET PREPERATION  
 
Included studies showed multiple treatment comparisons and comparisons varied 
from one study to another. We dummy coded and created sub category of HIV medicines 
for appropriate analysis purposes those attached in Appendix-3. We created sub classes 
for combination ART regimens. NRTI which compared alone with other ART was 
categorized as category 1. NNRTI alone, that compared with other ART considered as 
category 2. PI alone compared with other drugs considered as category 3. We found that, 
five studies considered and compared ritonavir boosted Lopinavir (LPV/r which is FDA 
approved HIV medicines under combination category) with other types of ART and we 
coded them as LPV/r containing combination category 4. PI medicines used in 
combination with ART and compared with combination ART drugs as PI containing 
combination ART category 5. NNRTI used along with combination ART and compared 
with different ART drugs as NNRTI containing combination ART category 6.  
 
STATISTICAL ANALYSIS 
 
 
 Inter rater reliability (IRR) was calculated for all continuous and categorical 
variables using IBM SPSS Statistical Version 22 (28). The kappa (κ) coefficient was 
0.94, resembling 94% agreement for categorical variables and agreement for Pearson’s 
correlation coefficient r =0.98 for numerical variables (29-30). For publication bias, we 
assessed asymmetries by using Begg, Egger, trim and fill statistical tests along with 
funnel plots. Publication bias was calculated and graphical statistics were plotted using R 
version 3.2.2 “metafor” package. 
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Using effect size calculator created by Huedo-Medina, effects for targeted 
outcomes were calculated (31). Standardized mean change following Becker’s d equation 
shown below, was used to calculate the effect sizes as all outcome variables were 
continuous where standardized mean changes were the difference between the post-test 
and pre-test means for one sample, divided by the pre-test or post-test standard deviation. 
Standardized mean change was considered as effect size index that follows a normal 
distribution with a range from negative infinity to positive infinity which allows results 
from several designs to be compared and combined directly (32).   
Becker’s d equation:  
pre
prepost
SD
MM
d

  
To interpret effects on targeted outcomes, standardized d value can be 
classified as 0.25, 0.5 and 0.8 representing small, medium and large effects following 
Cohen’s classification. (Citation) Weighted mean effect size was calculated which 
weighted by the inverse of the variance of each study. As all included studies were not 
identical in their methods, we calculated random effects using random effects model 
assuming if, data is coming from different populations which controls for different 
samples and accounts for within and between study variances (33). To test heterogeneity, 
Q statistics and I2 index were calculated where Q represents significance of heterogeneity 
and I2 calculates the magnitude of heterogeneity for each treatment. (Ref)  
As this meta-analysis included 20 randomized trials with varying type of ART 
regimens, we assumed that all different ART treatment options are nested within studies 
and considered multilevel modeling approach. Statisticians described that for multiple-
treatment study, two or, more treatment groups could be compared with one single group 
considering as control (38). For multilevel modeling, we created subsample from the 
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original dataset for studies those reported same outcome of interest. As multilevel 
modeling is designed to analyze variables from different levels, using statistical model 
that properly includes the various dependency issues (39), the purpose of conducting this 
multilevel meta-analysis was to observe within and between variations in both study 
levels and treatment levels for each outcome variable. For analysis, we used “metafor” 
package in R software (40). We used mixed effects models for the multilevel meta-
analysis that controls for multiple comparisons using maximum likelihood (ML) method. 
To estimate degree of overall effect size change by each treatment, we consider Β-
coefficient which indicates how much the overall effect size decreased or, increased 
moving from the reference combination to the target combination. We considered chi-
square statistics to measure over all treatment variation when p<0.05. Q and its p value 
infer if the unexplained variance is still significant. We used “mods” command in R 
software for moderation analysis to assess the relationship between study level covariates 
and effect sizes. The goal of the analysis was to examine to what extent the moderators 
included in the model influence the size of the average true effect (34). In addition to 
testing the impact of covariates for statistical significance, it is important to quantify the 
magnitude of their relationship with effect size. For this purpose, we used an index based 
on the percent reduction in true variance, analogous to the R² index with primary studies 
(35). To represent the relationship graphically we also performed plots using the moving 
constant technique explained by T. B. Huedo-Medina and the research team (36-37). 
Using restricted maximum likelihood (REML) method we added “Number of weeks” or, 
intervention period as moderator. 
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RESULTS 
 
 
Total participants were 2,592 HIV-infected positive population. Out of 2,592; 62 
people lost follow up, 829 withdraw the treatment, 976 discontinued, 135 patients 
reported toxicity and number of death report was 12. Mean age was 40.99± 3.07 (mean 
±SD) years, 80.4 % were male and 19.6% were female. Out of 20, 6 studies reported on 
ethnicity, among 1010 participants, 35.97 % were black, 64.03 % were non-Hispanic 
white. Mean CD-4 cell count was 363.57 ± 188.16 with intervention period of 84.4 
weeks. No significant asymmetry found for publication bias when begg’s and egger’s 
tests were performed to assess both inferential and graphical statistics which is provided 
in Table (2-6). 
 Random effects assumptions explained that body composition components 
weight increased for individual NRTI and PI treatment groups, LPV/r combination 
therapy but significantly (p= 0.0009) increased in LPV/r combination category [d+ = 
0.44, 95% CI (0.18 to 0.71)]. Body mass index increased in HIV patients when they were 
treated with individual NRTI and all three combination forms of HIV treatments (LPV/r, 
PI and NNRTI combination HAART) but significantly (p= <0.0001) increased in LPV/r 
combination therapy category [d+ = 0.94, 95% CI (0.53 to 1.3)] only. Trunk fat increased 
significantly (p=0.005) in NRTI alone treatment group with mild effect [d+ = 0.27, 95% 
CI (0.06 to 0.49)] and limb-fat increased in all treatment groups but significantly 
increased (p= <0.0001) in PI combination therapy with moderate efficacy [d+ = 0.44, 
95% CI (0.26 to 0.63)]. 
For lipid parameters, HDL increased for all treatment groups but significantly 
increased when patients received all combination ART or, HAART (LPV/r, PI and 
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NNRTI) with moderate to high efficacy [d+ = 0.75, 95% CI (0.40 to 1.09)], [d+ = 0.42, 
95% CI (0.06, 0.78)] and [d+ = 0.85, 95% CI (0.54 to 1.15)] respectively. Level of LDL 
or, bad cholesterol reduced in NRTI and PI alone treatment groups and PI combination 
HAART group but did not reduced significantly after interventions. To observe the 
overall effect sizes either favoring the baseline or, favoring different ART interventions, 
we used forest plots to draw graphical relations provided in Figure (8- 13). 
 
Our result on multilevel analysis clarifies that estimates for HDL were statistically 
significantly different in combination ART (LPV/r, PI and NNRTI) with p= <0.0001, 
p=0.0130, p= <0.0001respectively. For LDL, estimates were significantly different in 
NNRTI, LPV/r combined ART and NNRTI combined HAART. In addition, multivariate 
estimates for triglyceride were statistically significantly different for both alone and in 
combination HAART with p=<0.0001 for NRTI, p=<0.0001 for NNRTI, p=0.0038 for 
LPV/r combined HAART, p= <0.0001 for PI combined HAART and p=<0.0001 for 
NNRTI combined HAART, except for PI alone category. For trunk and limb-fat, 
variations were statistically significantly different in PI group and NNRTI combination 
HAART group, with corresponding p=<0.0001. Detail information is provided in Table-
12. 
From the result output, it represents that   intervention period or “number of 
weeks” act as a strong moderator for LDL [(β= -0.0049), 95% CI (-0.0079, -0.0018)] 
with significance level of p=<0.0001 indicating that if patients receiving treatment for 
long time LDL is reduced by 0.0049 units. For body fat constituents, our moderator 
analysis revealed that, level of trunk and limb fat increases [(β= (0.0033), 95% CI (-
0.0020, 0.0086)] and [(β= (0.0025), 95% CI (-0.0040, 0.0090)] as length of HIV 
18 
 
medication/number of week increases, but not significantly. Figure (2-7) for meta-
regression plots provided moderation pattern with solid dark red regression line and 95% 
confidence band under mixed-effects assumptions. 
To evaluate the progress of research focusing on body habitus change considering 
limb fat loss/lipoatrophy a big concern due to prolong ART use, we considered 
“Publication Year” as moderator variable and found that, limb fat increased 0.063 units 
and we could interpret that, due to the research advancement limb fat increased 
[(β=0.0639), 95% CI (0.006, 0.12)] with p= <0.0001 when patients received HIV 
treatment. For lipid parameters, Publication Year has significant moderation effects on 
HDL, LDL and TG variables [(β =-0.06), 95% CI (-0.01, -0.02)], [(β =-0.005) 95% CI (-
0.007, -0.001)] and [(β =-0.069), 95% CI (-0.11, -0.02)] with p=<0.0001, p=0.002 and 
p<0.0001 respectively. We did not find significant effects on weight and BMI while we 
use “Publication Year” as moderator into out model. 
Female patients act as a strong moderator variable for HDL and LDL. Mixed 
effects models explained that, level of HDL and LDL decreases [(β=-0.006), 95% CI (-
0.01, -0.0015)], [(β=-0.01), 95% CI (-0.019, -0.005)] significantly (p=<0.0001), if the 
number of female population increases, followed by no significant moderation effects on 
weight, BMI, trunk fat, limb fat, cholesterol and TG. 
Average mean age of HIV patients also acts as a strong moderator variable for 
cholesterol [(β=-0.17), 95% CI (-0.23, -0.10)] and TG [(β=-0.07) 95% CI (-0.11, -0.04)], 
pointing that, level of blood cholesterol and TG decreases due to the aging process. 
Methodological quality score has significant (p=<0.0001) moderation effect on 
Limb fat variable only and we can explain that, level of limb fat increases [(β = 0.18), 
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95% CI (0.005, 0.36)] in the studies those followed appropriate methodology or, 
maintained research quality. Criteria to assess quality of a study need to be addressed 
carefully to improve methodological quality score which might act as a strong moderator 
to impact on other targeted outcome variables.  In-detail information is provided in 
Table-13. List of moderators with no significant results and variables unable to use as 
moderators due to lack of study reports are also provided in Table (14-15). 
 
DISCUSSION 
 
This meta-analysis of randomized clinical trials was uniquely able to assess changes in 
weight, body mass index, trunk fat limb fat and lipid parameters considering both 
individual (NRTI, NNRTI, PI) treatment category and three combination HAART 
following FDA approved classifications of HIV medicines. 
Five studies provided pre-post data on weight. Overall, effect sizes indicated that 
body weight tends to increase in NRTI alone group, PI and LPV/r combination HAART 
groups in mild to moderate extents after intervention but did not increased significantly. 
Out of twenty, six studies quantified body mass index data after ART therapy with no 
study reports on overweight or, obesity. For waist circumference, seven studies reported 
baseline information on waist circumference but only three studies reported on post ART 
intervention data. We could not be capable to get different ART effects on waist 
circumference and waist-hip ratio due to lack of study reports. Body mass index 
increased after intervention in NRTI alone group, LPV/r combination, PI combination 
and NNRTI combination HAART categories but did not increased significantly. We, 
therefore, can state that decent increase of weight and BMI is beneficial for HIV infected 
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patients as wasting is a huge concern in HIV patients. It could have been alarming if we 
get significant increase on weight and BMI, which could be indicative and supportive of 
the prevalence of overweight and obesity in HIV- patients.  
For trunk-fat, eleven studies reported on pre-post assessments. Trunk fat did not 
increase significantly after intervention for all ART regimens except for individual NRTI. 
Total ten studies reported on limb-fat. Our study results showed significant increase on 
limb-fat when patients were NRTI alone and PI combination HAART category. For total 
body fat measure, eight studies provided post data and we found that, total body fat 
increased significantly in NRTI and LPV/r combination HAART categories.  
For lipid parameters, HDL which is considered ‘good cholesterol’ increased in all 
ART regimens, but significantly increased in NNRTI combination ART with high 
efficacy. LDL decreased after intervention in NRTI and PI alone treatment categories. 
Triglyceride levels decreased significantly after intervention those received PI alone 
group. In the moderator analysis, we found that the number of weeks has negative effect 
on LDL, indicating that, as number of weeks increased, the level of LDL decreased 
significantly in NRTI and PI alone groups. We can stablish our first and second 
hypothesis that, all treatment groups have impacts on weight, BMI, trunk fat, limb fat, 
lipids as part of body habitus and able to explain the variability.  
For the multilevel meta-analysis, impacts of NRTI alone, PI alone and LPV/r 
combination HAART categories differ significantly for weight and three combination 
groups differ significantly for body mass index (BMI). Effect size for HDL was 
statistically significantly different while patients were receiving LPV/r, PI and NNRTI 
combination HIV medications. For LDL, effect size was significantly different between 
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LPV/r and NNRTI combination therapy categories and NNRTI alone category. In 
addition, effect size was significantly different in LPV/r combination and NNRTI 
combination HAART categories for cholesterol. For triglyceride, impacts of all ART 
groups were significantly different except PI alone group. LPV/r and NNRTI 
combination form of antiviral medications were statistically significantly different from 
each other for trunk and limb fat. Thus, we can comply our third hypothesis that, formed 
ART treatments groups were statistically significantly different from each other 
considering all outcome variables. 
We included treatment period or, length of intervention as weeks, publication 
year, mean age, female gender, proportion of white population, methodological quality as 
potential moderators to perceive how much they modify the result when included into our 
multilevel moderation model. From results, we can infer that intervention period has a 
significant moderation effect on LDL only. Publication year displayed significant 
moderation effect on limb fat, HDL, and triglyceride. In addition, female gender modified 
HDL and LDL significantly, mean age of HIV patients has significant moderation effects 
on cholesterol and triglyceride, proportion of white population has significant moderation 
effect on trunk fat, limb fat, cholesterol and methodological quality modified only limb 
fat. From our study, we were not able to clarify moderation effects on weight, BMI, 
considering variables as potential moderators and unable to stablish our fourth research 
hypothesis. 
We collected information if studies conveyed information on mode of HIV 
infection. Total seven studies reported on route of HIV transmission. As different mode 
of HIV spread, six studies reported on homosexual character/patients having sex with 
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same gender, five studies reported on heterosexuality, three studies reported proportion of 
population used drugs. As risk characteristics/comorbid health status, we considered high 
blood pressure as one of major cardiovascular disease condition, diabetes and smoking 
habits. Three studies reported on diabetes, one study reported on smoking and no studies 
reported on blood pressure measures. It could have been interesting to perceive the 
moderation effects of specific moderators on weight, BMI, body fats and lipid parameters 
to help reduce the chances of chronic associated health fatalities in HIV patients as HIV 
itself leads to life threatening conditions in the long run if not treated properly. 
Risk of Bias 
 
Out of twenty included studies, nine reported on random sequence generation and 
allocation concealment. For blinding of participants, 10 studies reported on open label 
resembling of “high risk of bias”; three studies reported on single blinding; two studies 
reported on double blinding; 4 studies did not report on blinding of participants and 
reported as “unclear”.  One study was blinded at the beginning but un-blinding done by 
data safety and monitoring board. Two studies reported on blinding of outcomes, two 
studies reported on incomplete outcome data, one study on selective reporting and no 
studies reported on other bias category considering Cochrane criteria for judging Risk of 
Bias (24). Cochrane risk of bias is provided in Figure-14. Study design and protocol can 
be improved and addressed properly as randomization, allocation, blinding are important 
constructs in investigating the effects of methodological quality.  
Strengths and Limitations 
 
 This is the first meta-analysis that considered body habitus change targeting weight, body 
mass index, trunk fat and limb fat along with lipid parameter change after antiviral 
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treatment considering randomized clinical trials. We consider randomized controlled 
trials (RCTs) the best experimental design with less vulnerability to bias. This is an 
extension of classical meta-analysis that considered multilevel approach, which explains 
variability within and between studies in addition to help distinguishing differences in 
treatment levels considering different moderators for individual outcome variable. 
Moreover, this study considered FDA approved drug classifications which were last 
updated in 2015 and this helped our research team to create a sub class for combination 
forms of antiviral medicines or, HAART. 
 One possible limitation is due to time constraints, we were not able to collect raw 
data, as this would require too much time to contact study authors and few studies 
reported median value but not the mean value and we calculated the mean which might 
not be reliable to some extent. Secondly, three studies reported switching ART due to 
drug dose adverse effects during the intervention period and we could not be able to 
control that while analyzing data. Thirdly, we could not include five potential studies due 
to lack of appropriate data representations, as we did not hear back from authors 
requesting to get information of our variables of interest. It could have different impact 
on our result output along with the increase quantity of total sample size. In addition, due 
to lack of proper drug dose information, we could not include and compare ART 
regimens across specific dosages. This study might have been more informative if we 
could include different ART regimens along with dose information to observe specific 
drug dose effects on different outcomes before and after intervention.   
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CONCLUSIONS 
 
Our research team tried to explain degree of body habitus change by providing the 
extent of efficacy of each ART on weight, body mass index, limb fat, trunk fat and lipid 
parameters. Per our results, we can conclude that, different ART treatment interventions 
had different impacts on each outcome variable. LPV/r containing combination therapy is 
more beneficial for weight and BMI improvement. HIV patients those received 
combination ART along with protease inhibitors (PIs) had moderate beneficial effect on 
limb fat improvement than those were in other ART medications. For HDL, all three 
combination forms of ART are efficacious, but combination form of HIV medicines along 
with NNRTI exhibited high efficacy for HDL. For multilevel approach, each outcome 
variable was statistically significantly dissimilar from different treatment groups along 
with the significant heterogeneity by treatments. We also explained the degree of 
variability including publication year, number of weeks, number of female, methodological 
quality and average mean age as moderators and identified the statistic of residual variance 
and degree of residual variance those are still unexplained.  
In future direction, this study aims to conduct a network meta-analysis considering 
multiple ART regimens for comparing both direct comparisons of interventions with 
randomized trials and indirect comparisons across trials based on a common comparator. 
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RESEARCH CONTRIBUTIONS 
 
This study provided evidence to the HIV care providers addressing impacts of 
different antiretroviral medications in HIV patients emphasizing body habitus change as a 
sophisticated issue. Careful ART treatment is needed by establishing specific treatment 
protocol depending on severity of HIV infection while conducting ART interventions to 
minimize ART related fatal conditions and maintain body balance in HIV patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
 
 
REFERENCES 
 
1. Center for Disease Control and Prevention (CDC). Accessed from 
http://www.cdc.gov/hiv/statistics/overview/ataglance.html 
2. UNAIDS, UNAIDS report shows that 19 million of the 35 million people living with HIV 
today do not know that they have the virus. Geneva, 16 July 2014, accessed from  
http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2014/july
/20140716prgapreport 
3. HIV Treatment: FDA-Approved HIV Medicines. Accessed from 
https://aidsinfo.nih.gov/education-materials/fact-sheets/21/58/fda-approved-hiv-medicines# 
4. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision 
making. J Acquir Immune Defic Syndr. 2005; 39:395-400. 
5. Hayden RM. Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea 
in a human immunodeficiency virus infected patient following highly active antiretroviral 
therapy. Case report. The Journal of Cardio-metabolic Syndrome. 2008 
6. Bedimo JR. Body Fat Abnormalities in patients with HIV: Progress and Challenges. 
Journal of the International Association of Physicians in AIDS Care. 2008; Volume 7 
Number 6. 
7. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected 
patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592-
8. 
8. Palella FJ Jr, Cole SR, Chmiel JS, Riddler SA, Visscher B, Dobs A, Williams C. 
Anthropometrics and examiner reported body habitus abnormalities in the multicenter 
AIDS cohort study. Brief Report. Clinical Infectious Diseases 2004; 38(6):903-7. 
27 
 
 
 
9. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 
infection predicted by the quantity of virus in plasma. Science 1996; 272:1167–70. 
10. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on 
time to AIDS and death in men with known HIV infection duration. JAMA 1998; 
280:1497–1503. 
11. Carr A, Cooper DA. Images in clinical medicine. Lipodystrophy associated with an HIV-
protease inhibitor. N Engl J Med 1998; 339:1296. 
12. Heath KV, Hogg RS, Singer J, Chan KJ, O’Shaughnessy MV, Montaner JS. Antiretroviral 
Treatment patterns and incident HIV-associated morphologic and lipid abnormalities 
In a population-based cohort. J Acquir Immune Defic Syndr 2002; 30:440-7. 
13. Grinspoon S, Carr A (2005) Cardiovascular risk and body-fat abnormalities in HIV-
infected adults. N Engl J Med 352: 48–62. 
14. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome. Report of 
the National Heart, Lung and Blood Institute/American Heart Association Conference on 
Scientific Issues Related to Definition. Circulation 2004; 109:433- 8. 
15. Giralt M, Domingo P, Guallar JP, et al. HIV-1 infection alters gene expression in adipose 
tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antiviral Therapy. 
2006; 11:729-740. 
16. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 
2004; 89:2548-2556. 
17. Walmsley S, Cheung MA, Fantus G, Gough K, Smaill F, Azad A, Diog C, Raboud J. A 
prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected 
28 
 
 
 
patients initiating combination antiretroviral therapy. HIV Clinical Trials 2008; 9(5); 314-
323. 
18. Carr A, Samaras K, Thorisdottir A. Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, 
prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, 
hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-9. 
19. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the 
treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 
317:185–91. 
20. Shepp DH, Ashraf A. Effect of didanosine on human immunodeficiency virus viremia and 
antigenemia in patients with advanced disease: correlation with clinical response. J Infect 
Dis 1993; 167:30–5. 
21. Carr A. HIV lipodystrophy: Risk factors, pathogenesis, diagnosis and management. AIDS 
2003; 17(Suppl1): S141–148. 
22. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside 
analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV 
infection. AIDS 2000; 14:1309–1316. 
23. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting 
(lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 
13:1659–1667. 
24. Walker UA, Bickel M, Lutke Volksbeck SI, et al. Evidence of nucleoside analogue 
reverse transcriptase inhibitor associated genetic and structural defects of mitochondria in 
adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29:117–121. 
29 
 
 
 
25. Chou R, Fu R, Huffman HL, Korthuis TP. Initial highly-active antiretroviral therapy with 
a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies 
between direct and indirect meta-analyses. Lancet 2006; 368:1503-15. 
26. Perez-Molina AJ, Domingo P, Martınez E, Moreno S. The role of efavirenz compared 
with protease inhibitors in the body fat changes associated with highly active antiretroviral 
therapy. Journal of Antimicrobial Chemotherapy (2008) 62, 234–245. 
27. Carr A. Cooper DA. Adverse effects of antiviral therapy. Lancet 2000; 356: 1423–30. 
28. IBM Corp. IBM SPSS statistics for windows. 2013. 
29. Cohen J. Weighted kappa: Nominal scale agreement with provision for scaled 
disagreement or, partial credit. Psychol Bull. 1968; 70(4):213-220. 
30. Bartko JJ. The intraclass correlation coefficient as a measure of reliability. Psychol Rep. 
1966; 19(1):3-11. 
31. Huedo-Medina, T. B. and Johnson, B. T. Estimating the standardized mean difference 
effect size and its variance from different data sources: A spreadsheet. 2011. 
32. Becker BJ. Synthesizing standardized mean-change measures. British Journal of 
Mathematical and Statistical Psychology. 1998; 41:257. 
33. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing 
heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006; 11(2):193-
206. 
34. Wolfgang Viechtbauer. Conducting Meta-Analysis in R with the metaphor Package. 
Journal of Statistical software. 2010; Volume 36, Issue 3. 
35. Michael Borenstein, L. V. Hedges, J. P. T. Higgins and H. R. Rothstein. Introduction to 
Meta-   Analysis. 2009; John Wiley & Sons, Ltd. ISBN: 978-0-470-05724-7. 
30 
 
 
 
  
36. B. T. JOHNSON AND T. B. HUEDO-MEDINA. Depicting estimates using the intercept 
in meta-regression models: The moving constant technique. Research Synthesis Methods, 
2(3), 204-220. (doi:10.1002/jrsm.49).  
37. Harris Cooper, Larry V. Hedges, Jeffrey C. Valentine. The Handbook of Research 
Synthesis and Meta-Analysis Second Edition. 2009; ISBN-13 / ISBN-10 978-0-87154-
163-5. 
38. Joop J. Hox, Mirjam Moerbeek, Rens van de Schoot. Multilevel Analysis: Techniques and 
Applications, Second Edition. 2010; books.google.com 
39. Wolfgang Viechtbauer. The metafor Package: A Meta-Analysis Package for R. Journal of 
Statistical Software. 2015. 
40. Julian PT Higgins and Sally Green. Cochrane Handbook for Systematic Reviews of 
intervention. Accessed from: 
http://handbook.cochrane.org/chapter_8/table_8_5_d_criteria_for_judging_risk_of_bias_i
n_the_risk_of.htm 
41. Bernardino JI, Pulido F, Martinez E, Arrizabalaga J, Domingo P, Portilla J, Ocampo 
A, Muñoz J, Torres R, Arribas JR. Switching to lopinavir/ritonavir with or without 
abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. 
J Antimicrob Chemother. 2013 Jun; 68(6):1373-81. doi: 10.1093/jac/dks540. 
42. Blümer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, 
Yki-Jarvinen H, Danner SA, Reiss P, Sauerwein HP. Zidovudine/lamivudine contributes 
to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 
2008 Jan 11; 22(2):227-36. 
31 
 
 
 
43. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, 
Law M, Cooper DA; Mitochondrial Toxicity (MITOX) Study Group. Abacavir 
substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. 
JAMA. 2002 Jul 10; 288(2):207-15. 
44. Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Genin MA, Molina 
JM, Bouchaud O, Katlama C, Costagliola D. Initial therapy with nucleoside reverse 
transcriptase inhibitor-containing regimens is more effective than with regimens that spare 
them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. J 
Antimicrob Chemother. 2008 Oct; 62(4):797-808. doi: 10.1093/jac/dkn278. 
45. Feeney ER, van Vonderen MG, Wit F, Danner SA, van Agtmael MA, Villarroya F, 
Domingo P, Capeau J, Reiss P, Mallon PW. Zidovudine/lamivudine but not nevirapine in 
combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial 
DNA. AIDS. 2012 Nov 13; 26(17):2165-74. doi:10.1097/QAD.0b013e328358b279. 
46. Kolta S, Flandre P, Van PN, Cohen-Codar I, Valantin MA, Pintado C, Morlat P, Boue F, 
Rode R, Norton M, Knysz B, Briot K, Roux C, Delfraissy JF. Fat tissue distribution 
changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the 
MONARK trial. Curr HIV Res. 2011 Jan; 9(1):31-9.32.  
47. Lowe SH, Hassink EA, van Eck-Smit BL, Borleffs JC, Lange JM, Reiss P. Stavudine but 
not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from 
the Antiretroviral Regimen Evaluation Study (ARES). HIV Clin Trials. 2007 Sep-Oct; 
8(5):337-44. 
48. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong 
N, Freund J, Cooper DA; Mitochondrial Toxicity Study Group. Reversibility of 
32 
 
 
 
lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to 
abacavir: the MITOX Extension Study. AIDS. 2004 Apr 30; 18(7):1029-36. 
49. McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, Myers L, Melbourne K, 
Ha B, Daar ES.Peripheral and central fat changes in subjects randomized to abacavir-
lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study 
A5224s. Clin Infect Dis. 2011 Jul 15; 53(2):185-96. doi: 10.1093/cid/cir324. 
50. McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana 
JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M. Changes in fat 
mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or 
tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials 
Group study A5224s, substudy of A5202. J Infect Dis. 2013 Feb 15; 207(4):604-11. doi: 
10.1093/infdis/jis720. 
51. Milinkovic A, Martinez E, López S, de Lazzari E, Miró O, Vidal S, Blanco JL, Garrabou 
G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J,Gatell JM. The 
impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body 
composition and mitochondrial function in HIV-infected patients. Antivir Ther. 2007; 
12(3):407-15. 
52. Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya 
A, Murphy M, Scullard G, Leen C, Reilly G; RAVE (Randomized Abacavir versus Viread 
Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as 
replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006 Oct 24; 
20(16):2043-50. 
33 
 
 
 
53. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. 48-week, randomized, 
open-label comparison of three abacavir-based substitution approaches in the management 
of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003 May 1; 
33(1):22-8. 
54. Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw 
AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW, Rousseau F;FTC-301A 
Study Team. Efficacy and safety of emtricitabine vs stavudine in combination therapy in 
antiretroviral-naive patients: a randomized trial. JAMA. 2004 Jul 14; 292(2):180-9. 
55. Shlay JC, Bartsch G, Peng G, Wang J, Grunfeld C, Gibert CL, Visnegarwala F, Raghavan 
SS, Xiang Y, Farrough M, Perry HE, Kotler D, El-Sadr WM. Long-term body 
composition and metabolic changes in antiretroviral naive persons randomized to protease 
inhibitor, nonnucleoside reverse transcriptase inhibitor, or protease inhibitor plus 
nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic 
Syndr. 2007 Apr 15; 44(5):506-17. 
56. Shlay JC, Visnegarwala F, Bartsch G, Wang J, Peng G, El-Sadr WM, Gibert C, Kotler D, 
Grunfeld C, Raghavan S; Terry Beirn Community Programs for Clinical Research on 
AIDS (CPCRA). Body composition and metabolic changes in antiretroviral-naive patients 
randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune 
Defic Syndr. 2005 Feb 1; 38(2):147-55. 
57. Valantin MA, Kolta S, Flandre P, Algarte Genin M, Meynard JL, Ponscarme D, Slama L, 
Cuzin L, de Kerviler E, Inaoui R, Katlama C. Body fat distribution in HIV-infected 
patients treated for 96 weeks with darunavir/ritonavir monotherapy versus 
darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-
34 
 
 
 
ANRS136 substudy. HIV Med. 2012 Sep; 13(8):505-15. doi: 10.1111/j.1468-
1293.2012.01004.x. 
58. Valantin MA, Lanoy E, Bentata M, Kalmykova O, Boutekadjirt A, Allavena C, 
Rozenbaum W, Peytavin G, Amellal B, Calvez V, Costagliola D, Katlama C. A Recovery 
of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in 
patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. 
HIV Med. 2008 Oct; 9(8):625-35. doi: 10.1111/j.1468-1293.2008.00606.x.  
59. Marit G. A. van Vonderen , Michiel A. van Agtmael, Elly A. M. Hassink, Ana 
Milinkovic, Kees Brinkman, Suzanne E. Geerlings, Matti Ristola, Arne van Eeden, Sven 
A. Danner, Peter Reiss, for the MEDICLAS study groupZidovudine/Lamivudine for HIV-
1 Infection Contributes to Limb Fat Loss May 21, 
2009http://dx.doi.org/10.1371/journal.pone.0005647. 
60. Yang Y, Wilder-Smith A, Panchalingam A, Tha NO, Paton NI. Changes in body fat 
measured by DEXA in patients taking different formulations of stavudine. HIV Clin 
Trials. 2005 Nov-Dec; 6(6):337-43. 
61. Mills EJ, Kelly S, Bradley M, Mollen P, Cooper C, Nachega J. Antiretroviral effects on 
HIV-1 RNA, CD4 Cell count and progression to AIDS or death: a meta-regression 
analysis. HIV Med. 2008 Nov;9(10):849-57. 
62. Amorosa, V., Synnestvedt, M., Gross, R., Friedman, H., MacGregor, R. R., & Gudonis, 
 G., (2005). A tale of 2 epidemics: The intersection between obesity and HIV  infection in 
Philadelphia. AIDS, 39(5), 557-561. 
63. Boodram, B., Plankey, M. W., Cox, C., Tien, P.C., Cohen, M. H., Anastos, K., et al. 
(2009). Prevalence and correlates of elevated body mass index among HIV-Positive and 
35 
 
 
 
HIV-Negative Women in the Women's Interagency HIV Study. AIDS Patient Care and 
STDs, 23(12), 1009–1016. 
64. Crum-Cianflone, N., Roediger, M. P., Eberly, L., Headd, M., Marconi, V., Ganesan, A., et 
al. (2010). Increasing Rates of Obesity among HIV-Infected Persons during the HIV 
Epidemic. (M. R. Loutfy, Ed.) PLoS ONE, 5(4), e10106.  
65. Moore, R. D. & Chaisson, R. E. (1999). Natural history of HIV infection in the era of 
 combination antiretroviral therapy. AIDS, 13, 1933-1942. 
66. Andany N, Raboud MJ, Walmsley S, Diong C, Rourke BS, Rueda S, Rachlis A,Wobeser 
W, MacArthur DR, Binder L, Rosenes R, and Loutfy RL. Ethnicity and Gender 
Differences in Lipodystrophy of HIV-Positive Individuals Taking Antiretroviral Therapy 
in Ontario, Canada. HIV Clin Trials 2011;12(2):89–103. 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
 
 
FIGURES 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study identification and selection process using PRISMA diagram 
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Figure 2: Meta Regression plot for TG in PI regimen. 
Figure 3: Meta Regression plot for LDL in NRTI regimen.  
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Figure 4: Meta Regression plot for LDL in PI regimen.  
 
Figure 5: Meta regression plot for Limb fat in LPV/r combination category 1. 
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Figure 6: Meta Regression plot for Trunk-fat in LPV/r combination HAART 
category 1.  
 
 
 
Figure 7: Meta regression plot for Cholesterol in NNRTI combination HAART 
category 3. 
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Figure 8: Forest plot for Trunk Fat favors NRTI regimen 
Figure 9: Forest plot for Limb Fat Favors NNRTI Combination HAART category 3. 
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Figure 10: Forest plot for Total body fat favors NRTI  
Figure 11: Forest plot for HDL favors LPV/r Combination HAART category 1 
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Figure 12: Forest plot for HDL favors PI Combination HAART category 2 
 
 
 
 
 
Figure 13: Forest plot for HDL favors NNRTI Combination ART category 3 
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Figure 14: Cochrane Risk of Bias Table 
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TABLES 
Table 1: Summary of Included Literatures 
 
Author, year of 
publication 
Study 
duration 
Number of patients 
assessed 
Demographics 
Number of intervention groups 
along with treatment type 
Bernardino et al. 2012 96 weeks 88 Median age: 44.8 years 
Male: 59 (67%); Female: 29 (33%) 
Ethnicity: Not reported 
CD4 cell count: 697 median 
Toxicity reported: 13 
A. LPV/r monotherapy 
B. ABC/3TC + LPV/r triple therapy 
Total two groups 
Blumer et al. 2008 12 weeks 20 Median age: 42 years 
Male: 20 (100%) 
Ethnicity: Not reported 
CD4 cell count: 200 median 
Toxicity reported: 2 
A. LPV/r + ZDV/3TC 
B. LPV/r + NVP 
Total two groups 
Carr et al. 2002 24 weeks 111 Median age: 43.5 
Male: 105 (94.59%); Female: 6(0.05%) 
Ethnicity: Not reported 
CD4 cell count: 578.5  
Toxicity reported: 4 
A. Stavudine/Zidovudine 
B. AbacavirA 
Total two groups. 
Duvivier et al. 2008 48 weeks 117 Median age: 37.3 years 
Male: 87(74%); Female: 30(26%)  
Black: 42% 
CD4 cell count: 207 median 
CDC stage not reported 
A. NRTI containing regimen: PI/r plus 
two NRTI 
Or, NNRTI plus two NRTIs 
B. NRTI-sparing regimen: NNRTI plus 
boosted PI/r. 
Total three groups. 
Feeney et al. 2012 144 weeks 48 Median age: 59.5 years 
Male: 48(100%) 
White race: 81% 
CD4 cell count: 212.5 median 
CDC stage reported 
Toxicity reported: 10 
A: NRTI containing regimen ZDV/3TC 
with LPV/r 
B: NRTI-sparing regimen NVP with 
LPV/r. 
Total two groups. 
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Kolta et al. 2011 48 weeks 136 
DEXA data contain 
subsample of 63 
patients  
Mean age: 36 years 
Male: 89(65.44%); Female: 47(34.56%) 
Ethnicity: Not reported 
CD4 cell count: 238.5 mean 
A. LPV/r Monotherapy 
B. LPV/r+ZDV/3TC 
Total two groups 
Lowe et al. 2007 96 weeks 19 Median age: 43.73 years 
Male: 16 (84.21%); Female: 3(15.79%) 
Ethnicity: Not reported 
CD4 cell count: 173.33 median 
A. NFV/ddl 
B. NVP/ddl/3TC 
C. SQV-r/ddl/3TC 
Total three groups 
Martin et al. 2004 72 weeks 111 Median age: 43.5 
Male: 105 (94.59%); Female: 6(5.41%) 
Ethnicity: Not reported 
CD4 cell count: 578.5 
Toxicity reported: 4 
A. ZDV/d4T 
B. Abacavir 
Total two groups 
McComsey et al. 
2011 
96 weeks 269 Median age: 38 years 
Male: 229(85%); Female: 40(15%) 
White (Non-Hispanics): 47% 
CD4 cell count: 233 median 
Toxicity reported: 44 
A. EFV+TDF-FTC 
B. EFV+ABC-3TC 
C. ATV-rtv + TDF-FTC 
D. ATV-rtv + ABC-3TC 
Total four groups 
McComsey et al. 
2013 
96 weeks 56 Median age: 39 years 
Male: 49(87%); Female: 7(13%) 
White (Non-Hispanics): 39% 
CD4 cell count: 227 median 
A. ABC/3TC 
B. TDF/FTC 
C. EFV 
D. ATV/r 
Total four groups 
Milinkovic et al. 2007 24 weeks 58 Median age: 43 years  
Male: 54 (93.10%); Female: 4(6.90%) 
Ethnicity: Not reported 
CD4 cell count: 587 median 
Toxicity reported: 1 
A. d4T40 
B. d4T30 
C. TDF 
Total three groups 
Moyle et al. 2006 48 weeks 105 Mean age: 42.5 years 
Male: 95 (90.47%); Female: 10(9.53%) 
Ethnicity: not reported 
CD4 cell count: 503.5 
Toxicity reported: 4 
A. Tenofovir DF 
B. Abacavir 
Total Two groups 
Moyle et al. 2003 48 weeks 30 Mean age: 42 years 
Male: not reported 
White: 
A. d4T with ABC 
B. PI or NRTI with ABC 
46 
 
 
 
CD4 cell count: 540.5 
Toxicity reported: 1 
C. d4T and PI or NNRTI with 
ABC+AZT 
Total three groups 
Saag et al. 2004 60 weeks 571 Mean age: 36.15 years 
Male: 485 (84.93%) 
Female: 86 (15.07%) 
Ethnicity:  
Toxicity reported: 56 
A. ZDV/d4T 
B. Abacavir 
Total two groups 
Shlay et al. 2007 248 weeks 422 Mean age: 38 years 
Male: 333 (79%) 
Female: 89(21%) 
Black: 60% 
CD4 cell count not reported 
A. PI 
B. NNRTI 
C. PI+NNRTI 
Total three groups 
Shlay et al. 2005     128 weeks 96 Mean age: 36.5 years 
Male: 69(71.9%) 
Female: 27(28.1%) 
Black: 63.5% 
CD4 cell count: 237 median 
A. ddI+d4T 
B. ABC+3TC  
Total two groups. 
 
Valantin et al. 2012 96 weeks 156 Median age: 45 years 
Male: 121 (77.6%); Female: 35(22.4%) 
Race: Not reported 
Baseline CD4 cell counts: Not reported  
A. Darunavir/r monotherapy 
B. Darunavir/r triple therapy 
Total two groups. 
Valantin et al. 2008 96 weeks 100 Median age: 44.5 years 
Male: 79(79%); Female: 21 (21%) 
Homosexuals: 51% 
CD4 cell count: 610 median 
CDC stage reported 
Toxicity reported: 18 
A. NRTI maintaining group 
B. NRTI sparing regimen NNRTI and PI 
Total two groups. 
Vonderen et al. 2009 96 weeks 50 Median age: 40.5 years 
Male: 50(100%) 
White: 81% 
CD4 cell count: 212.5 median 
Toxicity reported: 7 
A. ZDV/3TC/LPV/r 
B. NVP/LPV/r 
Total two groups 
Yang et al. 2005 72 weeks 29 Mean age: 42.45 years 
Male: 21 (72.41%); Female: 8 (27.59%) 
Ethnicity: Not reported 
CD4 cell count: 552.5 mean 
A. ER 
B. IR 
Total two groups 
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Table 2: Publication Bias for NRTI 
 
Outcome S Begg’s Egger’s 
Weight 3 1 0.5259 
BMI 3 0.3333 0.1745 
Trunk-fat 10 0.7275 0.2908 
Limb-fat 8 0.7195 0.3846 
Total Body 
fat 
12 0.7373 0.3638 
Cholesterol 11 1 0.9925 
HDL 12 0.6384 0.3821 
LDL 13 0.5900 0.7326 
TG 13 0.9524 0.0956 
    
 
 
Table 3: Publication Bias PI 
 
Outcome S Begg’s Egger’s 
Weight Won’t run   
BMI No data   
Trunkfat Won’t run   
Limbfat Won’t run   
Total Body fat Won’t run   
Cholesterol    
HDL 3 1 0.4416 
LDL 3 1 0.2044 
TG 3 1 0.4297 
 
 
Table 4: Publication Bias Combined Drug Category 1 
 
Outcome S Begg’s Egger’s 
Weight 4 0.75 0.7444 
BMI 2 1 N/A 
Trunkfat 8 0.9049 0.9076 
Limbfat 4 1 0.3024 
Total Body 
fat 
6 0.0167 0.0386 
Cholesterol 8 0.1789 0.008 
HDL 8 0.1789 0.0452 
LDL 8 0.0610 0.012 
TG 8 0.0610 0.0021 
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Table 5: Publication Bias Combined Drug Category 2 
 
Outcome S Begg’s Egger’s 
Weight WON’T RUN   
BMI 5 0.0833 0.0473 
Trunkfat 6 0.4694 0.0290 
Limbfat 10 0.2912 0.3144 
Total Body 
fat 
2 1 N/A 
Cholesterol 5 0.2333 0.2940 
HDL 4 0.7500 0.3432 
LDL 6 0.2722 0.5953 
TG 6 0.4694 0.2602 
 
 
Table 6: Publication Bias for ART Combined Drug Category 3 
 
Outcome S Begg’s Egger’s 
Weight 2 1 N/A 
BMI 5 0.8167 0.4433 
Trunkfat 2 1 N/A 
Limbfat 2 0.2333 0.2625 
Total Body 
fat 
3   
Cholesterol 3 1 0.2712 
HDL 3 0.3333 0.5442 
LDL 3 0.3333 0.0548 
TG 3 1 0.6178 
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Table 7: Overall Effect Sizes (RE) and Homogeneity assumptions for NRTI alone 
 
   d (95% CI)  
Homogeneity of effect 
sizes I2 (95% CI) 
Outcome k Random-Effects  Q P-value 
Weight 3 0.20 (0.03, 0.37)  0.23 0.88 0 
BMI 3 0.20 (0.03, 0.37)  0.07 0.96 0 
Trunk fata 10 0.27 (0.06, 0.49)  23.39 0.005 65.74 
Limb-fat 8 0.18(-0.27, 0.65)  40.21 <0.0001 87.60 
Total Body Fata 12 0.26 (0.02, 0.50)  34.69 0.0003 72.71 
Cholesterol 11 -0.04 (-18, 0.09)  17.26 0.06 39.34 
HDL 12 0.002 (-0.11, 0.12)  15.29 0.16 25.00 
LDL 13 -0.13(-0.24, 0.02)  17.50 0.13 14.35 
TG 13 -0.02 (-0.12, 0.07)  0.002 0.002 0.02 
a Significant Outcomes 
 
 
Table 8: Overall Effect Sizes (RE) and Homogeneity assumptions for PI alone 
 
   d (95% CI)  
Homogeneity of effect 
sizes I2 (95% CI) 
Outcome k Random-Effects  Q P-value 
Weighta 2 0.32 (-0.08, 0.72)  5.99 0.01 83.32 
BMI No data      
Trunk fat 2 0.46 (0.29, 0.63)  0.49 0.48 0 
Limbfat 2 0.27 (0.11, 0.43)  0.24 0.61 0 
Total Body Fat No data      
Cholesterol 2 0.06 (-0.10, 0.22)  0.18 0.67 0 
HDL 3 0.05 (-0.13, 0.24)  3.89 0.14 48.75 
LDLa 3 -0.30 (-0.76, 0.15)  18.13 0.0001 90.30 
TGa 3 -0.05 (-0.42, 0.31)  13.42 0.0012 85.71 
a Significant Outcomes 
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Table 9: Overall effect sizes (RE) and homogeneity assumptions for LPV/r 
combination category 
 
  d (95% CI)  
Homogeneity of effect 
sizes I2 (95% CI) 
Outcome k Random-Effects  Q P-value 
Weighta 4 0.44 (0.18, 0.71)  3.34 0.0009 14.49  
BMIa 2 0.94 (0.53, 1.34)  0.01 <.0001 0.00  
Trunk-fat 8 0.01 (-0.31, 0.34)  29.34 0.91 79.16  
Limb-fat 4 0.10 (-0.31, 0.52)  15.24 0.61 82.68  
Total Body Fata 6 0.39 (0.12, 0.65)  12.76 0.003 61.97  
Cholesterola 8 0.64 (0.21, 1.07)  42.30 0.003 82.34  
HDLa 8 0.75 (0.40, 1.09)  25.78 <.0001 72.63  
LDLa 8 0.69 (0.20, 1.18)  45.93 0.005 86.78  
TGa 8 0.56 (0.14, 0.98)  38.61 0.008 82.20  
a Significant Outcomes 
 
 
 
 
Table 10: Overall effect sizes (RE) and homogeneity assumptions for PI 
combination category 
 
 
   d (95% CI)  
Homogeneity of effect 
sizes I2 (95% CI) 
Outcome k Random-Effects  Q P-value 
Weight 1 (FE)     
BMIa 5 0.36 (0.19, 0.54)  2.73 <.0001 0.01 
Trunk-fat 6 0.61 (0.42, 0.80)  2.35 <.0001 0.00 
Limb-fata 10 0.44 (0.26, 0.63)  12.59 <.0001 33.21 
Total body fat 2 0.02 (-0.49, 0.53)  0.13 0.93 0.00 
Cholesterol 5 0.05 (-0.91, 1.10)  41.63 0.91 95.05 
HDLa 4 0.42 (0.06, 0.78)  18.63 0.01 82.08 
LDL 6 -0.14 (-0.87, 0.59)  74.65 0.70 92.91 
TG 6 0.06 (-0.37, 0.49)  21.29 0.77 84.27 
a Significant Outcomes 
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Table 11: Overall effect sizes (RE) and homogeneity assumptions for NNRTI 
combination category 
 
   d (95% CI)  
Homogeneity of effect 
sizes I2 (95% CI) 
Outcome k Random-Effects  Q P-value 
Weight 2 -0.01 (-0.57, 0.54)  21.72 0.95 95.40 
BMI 5 0.23 (-0.11, 0.57)  28.89 0.18 83.50 
Trunk-fat 2 0.46 (0.26, 0.67)  0.03 <.0001 0.00 
Limb-fat 5 0.51 (0.34, 0.69)  1.90 <.0001 0.00 
Total body fat       
Cholesterola 3 1.09 (0.74, 1.43)  5.38 <.0001 66.18 
HDLa 3 0.85 (0.54, 1.15)  4.92 <.0001 59.59 
LDL 3 0.54 (0.37, 0.70)  1.32 <.0001 0.00 
TGa 3 0.41 (0.10, 0.72)  6.18 0.008 70.28 
SAT       N/A      
VAT 4 0.29 (0.12, 0.47)  2.02 0.0010 0.00 
TAT N/A      
a Significant Outcomes 
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Table 12: Multilevel MA model results on different outcomes in different ART 
treatment levels 
 
Outcome k 
Β-coefficient 
(95% CI) ART treatment levels 
χ² statistics (Q) 
p-value 
Weight 12 
NRTI alone: 0.02 (0.03,0.38) 
                PI alone: 0.33 (0.17, 0.50) 
               LPV/r comb: 0.43 (0.18, 0.68) 
<0.0001 
BMI 15 
LPV/r comb: 0.94 (0.53, 1.34) 
                PI comb: 0.62 (0.28, 0.97) 
               NNRTI com: 0.02 (0.07, 0.9) 
<0.0001 
Trunk-fat 26 
PI alone: 0.47 (0.30, 0.64) 
NNRTI comb: 0.85 (0.01, 1.69) 
<0.0001 
Limb-fat 27 
PI alone: 0.27 (0.1145, 0.4397) 
NNRTI comb: 1.05 (0.21, 1.89) 
<0.0001 
Cholesterol 29 
LPV/r comb: 0.92(0.29, 1.54) 
NNRTI comb: 1.65 (0.95, 2.35) 
<0.0001 
HDL 31 
LPV/r comb: 0.90 (0.47, 1.32) 
PI comb: 0.56 (0.11, 1.01) 
NNRTI comb: 1.09 (0.69, 1.49) 
<0.0001 
LDL 
 
34 
NNRTI: -1.08 (-1.99, 0.18) 
LPV/r comb: 0.94 (0.41, 1.47) 
NNRTI comb: 0.93 (0.26, 1.61) 
<0.0001 
TG 34 
NRTI alone: 3.57 (2.16, 4.98) 
NNRTI alone: 1.30 (0.79, 1.81) 
LPV/r comb: 1.002 (0.32, 1.68) 
PI comb: -1.83 (-2.75, -0.92) 
NNRTI comb: 1.28 (0.81, 1.76) 
<0.0001 
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Table 13: Multilevel MA model results including moderator analysis 
 
 
  Β-coefficient 
(95%CI) 
 
Homogeneity of effect 
sizes 
I2 (95% CI) 
Moderator 
Variable 
Outcome k   Q-statistic P-value 
Weeks Weight 
BMI 
Trunk fat 
12 
15 
26 
-0.002 (-0.008, 0.004) 
        0.002 (-0.003, 0.008) 
0.003 (-0.002, 0.008) 
 
19.84 
32.22 
30.40 
0.002 
<0.0001 
<0.0001 
55.63% 
46.28% 
55.97% 
 Limb-fat 27 0.003 (-0.004, 0.009)  32.99 <0.0001 58.35% 
 Cholesterol 29 -0.002 (-0.007, 0.004)  37.42 <0.0001 77.58% 
 HDL 31 -0.001 (-0.003, 0.0007)   88.54 <0.0001 46.03% 
 LDL* 34 -0.004 (-0.007, -0.002)  17.50 <0.0001 72.46% 
 TG 34 0.0006 (-0.002, 0.003)   22.86 0.0018 60.14% 
Publication Year Weight 
BMI 
Trunk fat 
12 
      15 
      26 
-0.02 (-0.1, 0.06)  
0.04 (-0.002, 0.07) 
-0.02 (-0.07, 0.03) 
 
19.75  
36.55  
32.35 
0.003 
<0.0001 
<0.0001 
55.55% 
42.39% 
52.39% 
 Limb-fat* 27 0.06 (0.006, 0.12)  41.51 <0.0001 53.57% 
 Cholesterol 29 -0.07 (-0.15, 0.0007)  5077 <0.0001 71.00% 
 HDL* 31 -0.06 (-0.01, -0.02)  103.76 <0.0001 39.50% 
 LDL* 34 -0.005 (-0.007, -0.001)  21.90 0.0026 81.95% 
 TG* 34 -0.07(-0.1, -0.02)  40.13 <0.0001 40.32% 
Female Weight 
BMI 
Trunk fat 
12 
.. 
26 
-0.003 (-0.04, 0.03) 
.. 
-0.007 (-0.016, 0.0006) 
 
19.48 
.. 
46.22 
0.003 
.. 
<0.0001 
55.50% 
.. 
41.27% 
 Limb-fat 27 -0.0019 (-0.014, 0.01)  29.62 <0.0001 62.21%  
 Cholesterol 29 0.0048 (-0.008, 0.02)  36.31 <0.0001 78.51%  
 HDL* 31 -0.006 (-0.01, -0.001)  101.60 <0.0001 39.78% 
 LDL* 34 -0.01 (-0.019, -0.005)  41.79 <0.0001 72.07% 
 TG 34 0.0012 (-0.004, 0.006)    22.63 0.0020 60.57% 
54 
 
 
 
Average mean age Weight  
BMI 
Trunk fat 
12 
15 
26 
          -0.04 (-0.58, 0.49) 
0.03 (-0.04, 0.09) 
0.02 (-0.03, 0.08) 
 
19.48 
32.54  
31.24 
0.003 
<0.0001 
<0.0001 
55.50%  
45.13% 
54.08% 
 Limb-fat 27             0.04 (-0.007, 0.10)  42.06 <0.0001 50.53%  
 Cholesterol* 29 -0.17 (-0.23, -0.10)  117.09 <0.0001 44.92%  
 HDL 31           -0.03 (-0.06, 0.01)  84.20 <0.0001 50.30% 
 LDL 34 0.001 (-0.06, 0.07)  21.87 0.0027 82.04% 
 TG* 34 -0.07 (-0.11, -0.04)    47.43 <0.0001 40.19% 
Prop of white Weight .. ..  .. .. .. 
 BMI 15 -0.41 (-1.67, 0.84)  32.28 <0.0001 45.22% 
 Trunk-fat* 26 0.64 (0.35, 0.92)  89.16 <0.0001 18.71% 
 Limb-fat* 27 0.73 (0.24, 1.23)   56.86 <0.0001 41.35% 
 Cholesterol* 29 0.50 (0.02, 0.97)  47.85 <0.0001 73.02% 
 HDL 31 0.24 (-0.08, 0.57)  82.53 <0.0001 51.75% 
 LDL 34 0.45 (-0.08, 1.0)  25.75 0.0006 80.70% 
 TG* 34 0.40 (0.07, 0.74)  32.28 <0.0001 51.16% 
MQ       Weight 12 0.07 (-0.17, 0.33)  19.87 0.002 56.59% 
       BMI 15 0.081 (-0.10, 0.26)  32.26  <0.0001 46.61% 
       Trunk-fat 26 0.003 (-0.002, 0.008)  30.40 <0.0001 55.97% 
        Limb-fat* 27 0.18 (0.005, 0.36)  38.73 <0.0001 56.39% 
        Cholesterol 29 -0.14 (-0.36, 0.06)  41.61 <0.0001 75.85% 
        HDL 31 -0.11 (-0.24, 0.01)  86.68 <0.0001 49.35% 
        LDL 34 -0.09 (-0.30, 0.12)  22.88 0.0018 81.83% 
        TG 34             -0.07 (-0.22, 0.07)  23.05 0.0017 61.76% 
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Table 14: List of moderators with no significant results 
 
 
 
 
 
 
 
 
Proportion of black population 
Proportion of Latino/Hispanic population 
Proportion of Asian population 
Proportion of other population 
Mean body fat% 
Mean sub-cutaneous adipose tissue 
Mean visceral adipose tissue 
Mean total adipose tissue 
Mean fasting blood glucose 
Mean fasting insulin level 
Mean CD4 cell counts 
Mean RNA level 
Proportion of population reported Homosexuality as HIV route of transmission 
Proportion of population reported Heterosexuality as HIV route of transmission 
Proportion of population reported to ART adherence 
Proportion of population reported on toxicity 
Type of intervention settings 
Number of intervention and comparison groups used 
Participants assigned in intervention and comparison groups 
Number of patients switched due to adverse drug reaction 
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Table 15: List of moderators unable to analyze due to lack of study reports 
 
 
 
 
 
 
 
 
 
Mean Height of population 
Mean waist-hip ratio of population  
Mean BMI Over Weight 
Mean BMI for Obese class1, class2, class3 
Mean mid arm area 
Mean mid-thigh area 
Mean Hgba1C % 
Proportion of population reported on drug use as HIV route of transmission 
Proportion of population reported on blood transfusion as HIV route of transmission 
Proportion of population reported on asymptomatic conditions 
Proportion of population reported on symptomatic conditions 
Proportion of population having Hepatitis B 
Proportion of population having hepatitis C 
Number of facilitator/provider 
ART dosage used 
Proportion of population having diabetes 
Proportion of population having high blood pressure 
Proportion of population having smoking habit 
Type of intervention settings 
Number of intervention and comparison groups used 
Participants assigned in intervention and comparison groups 
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APPENDIX 
 
Appendix 1: Comprehensive Literature Search Strategy 
 
Searches run July 6-7, 2015 
Total 506 citations after removing duplicates. 
To get your total # for the flow diagram, add the original results + the additional from 
revised search. Then subtract 2 duplicates. 
 
PubMed Search 
1940's to present 
Results: 427 
(HIV OR "HIV"[Mesh] OR "Acquired Immunodeficiency Syndrome"[Mesh]) AND 
(Overweight OR "Overweight"[Mesh] OR BMI OR "body mass" OR "Body Mass 
Index"[MeSH] OR "Waist Circumference"[MeSH] OR "Weight Gain"[Mesh] OR 
"weight gain" OR anthropometric[ti] OR obesity OR "Obesity"[Mesh] OR obese OR 
"abdominal fat" OR adiposity OR "body fat") AND (HAART OR "Antiretroviral 
Therapy, Highly Active"[Mesh] OR ART OR Antiretroviral* OR "Anti-retroviral" OR 
"Anti-retrovirals" OR "Anti-Retroviral Agents"[Mesh]) AND ("quasi-experimental" OR 
RCT OR "randomized controlled trial"[pt] OR (clinical[tiab] AND trial[tiab]) OR 
"clinical trials as topic"[mesh] OR "clinical trial" [pt] OR random*[tiab] OR "random 
allocation"[mesh] OR "therapeutic use"[sh]) AND Humans[mesh] NOT (pregnan* OR 
wasting OR "weight loss" OR Lipodystroph* OR fever OR hepatitis OR carcinogen* OR 
neoplasm* OR cancer OR cancers OR "chronic liver disease" OR "liver fibrosis" OR 
"fatty liver disease" OR atherosclerosis OR "urinary metabolites" OR "urinary 
abnormalities" OR "renal impairment" OR "renal dysfunction"  OR "bone mineral 
density" OR "skeletal muscle toxicity" OR "muscular dystrophy" OR "skeletal muscle 
disease" OR anemia OR tuberculosis OR "neurological disorder" OR "neurocognitive 
impairment" OR "lung disease" OR "alveolar disease" OR "genetic disease" OR "genetic 
abnormalities" OR biomarkers OR markers OR smoking[ti] OR dyslipidemi*[ti] OR 
dyslipidaemi*[ti] OR hypertriglyceridaemi*[ti]) 
Revised September 8, 2015: 360 after removing citations from original search 
(HIV OR "HIV"[Mesh] OR "Acquired Immunodeficiency Syndrome"[Mesh]) AND 
(Overweight OR "Overweight"[Mesh] OR BMI OR "body mass" OR "Body Mass 
Index"[MeSH] OR "Waist Circumference"[MeSH] OR "Weight Gain"[Mesh] OR 
"weight gain" OR anthropometric[ti] OR obesity OR "Obesity"[Mesh] OR obese OR 
"abdominal fat" OR adiposity OR "body fat" OR lipohypertrophy) AND (NNRTI OR PI 
OR "protease inhibitor" OR HAART OR "Antiretroviral Therapy, Highly Active"[Mesh] 
OR ART OR Antiretroviral* OR "Anti-retroviral" OR "Anti-retrovirals" OR "Anti-
Retroviral Agents"[Mesh]) AND ("quasi-experimental" OR RCT OR "randomized 
controlled trial"[pt] OR (clinical[tiab] AND trial[tiab]) OR "clinical trials as topic"[mesh] 
OR "clinical trial" [pt] OR random*[tiab] OR "random allocation"[mesh] OR 
"therapeutic use"[sh]) AND Humans[mesh] NOT (pregnan* OR wasting OR "weight 
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loss" OR fever OR hepatitis OR carcinogen* OR neoplasm* OR cancer OR cancers OR 
"chronic liver disease" OR "liver fibrosis" OR "fatty liver disease" OR atherosclerosis 
OR "urinary metabolites" OR "urinary abnormalities" OR "renal impairment" OR "renal 
dysfunction"  OR "bone mineral density" OR "skeletal muscle toxicity" OR "muscular 
dystrophy" OR "skeletal muscle disease" OR anemia OR tuberculosis OR "neurological 
disorder" OR "neurocognitive impairment" OR "lung disease" OR "alveolar disease" OR 
"genetic disease" OR "genetic abnormalities" OR biomarkers OR markers OR 
smoking[ti]) 
Scopus search: 
 
1823 to Present. 
Citations: 131. 
Limits: Article 
 
Concept 1: (HIV OR "Acquired Immunodeficiency Syndrome")  
 
AND  
 
Concept 2 part 1: (Overweight OR BMI OR "body mass" OR "Waist 
Circumference" OR "weight gain" OR obesity OR obese OR "abdominal fat" OR 
adiposity OR "body fat")  
OR 
Concept 2 part 2 (in article title): anthropometric 
 
AND  
 
Concept 3: (HAART OR ART OR Antiretroviral* OR "Anti-retroviral" OR 
"Anti-retrovirals")  
 
AND  
 
Concept 4 part 1: ("quasi-experimental" OR RCT OR "clinical trial" OR 
random*) 
OR 
Concept 4 part 2: (clinical AND trial) 
 
NOT  
 
Concept 5 part 1: (pregnan* OR wasting OR "weight loss" OR Lipodystroph* OR 
fever OR hepatitis OR carcinogen* OR neoplasm* OR cancer OR cancers OR 
"chronic liver disease" OR "liver fibrosis" OR "fatty liver disease" OR 
atherosclerosis OR "urinary metabolites" OR "urinary abnormalities" OR "renal 
impairment" OR "renal dysfunction"  OR "bone mineral density" OR "skeletal 
muscle toxicity" OR "muscular dystrophy" OR "skeletal muscle disease" OR 
anemia OR tuberculosis OR "neurological disorder" OR "neurocognitive 
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impairment" OR "lung disease" OR "alveolar disease" OR "genetic disease" OR 
"genetic abnormalities" OR biomarkers OR markers) 
OR  
Concept 5 part 2 (in article title): rat OR rats OR mice OR mouse OR dog OR 
dogs OR cats OR "cross-sectional study" OR "case report" OR comment OR 
editorial OR letter OR "case control" OR "case study" OR "case series" OR 
"follow-up study" OR "observational study" OR "prospective cohort" OR "cohort 
study" OR "longitudinal study" OR "retrospective study" OR "non-randomized" 
OR review OR smoking OR dyslipidemi* OR dyslipidaemi* OR 
hypertriglyceridaemi* 
 
 
Revised search:  after removing original: 16 
 
Concept 1: (HIV OR "Acquired Immunodeficiency Syndrome")  
 
AND  
Concept 2 part 1: (Overweight OR BMI OR "body mass" OR "Waist 
Circumference" OR "weight gain" OR obesity OR obese OR "abdominal fat" OR 
adiposity OR "body fat" OR lipohypertrophy)  
OR 
Concept 2 part 2 (in article title): anthropometric 
 
AND  
Concept 3: (HAART OR ART OR Antiretroviral* OR "Anti-retroviral" OR 
"Anti-retrovirals" OR NNRTI OR PI OR "protease inhibitor")  
 
AND  
Concept 4 part 1: ("quasi-experimental" OR RCT OR "clinical trial" OR 
random*) 
OR 
Concept 4 part 2: (clinical AND trial) 
 
NOT  
Concept 5 part 1: (pregnan* OR wasting OR "weight loss" OR Lipodystroph* OR 
fever OR hepatitis OR carcinogen* OR neoplasm* OR cancer OR cancers OR 
"chronic liver disease" OR "liver fibrosis" OR "fatty liver disease" OR 
atherosclerosis OR "urinary metabolites" OR "urinary abnormalities" OR "renal 
impairment" OR "renal dysfunction"  OR "bone mineral density" OR "skeletal 
muscle toxicity" OR "muscular dystrophy" OR "skeletal muscle disease" OR 
anemia OR tuberculosis OR "neurological disorder" OR "neurocognitive 
impairment" OR "lung disease" OR "alveolar disease" OR "genetic disease" OR 
"genetic abnormalities" OR biomarkers OR markers) 
OR  
Concept 5 part 2 (in article title): rat OR rats OR mice OR mouse OR dog OR 
dogs OR cats OR "cross-sectional study" OR "case report" OR comment OR 
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editorial OR letter OR "case control" OR "case study" OR "case series" OR 
"follow-up study" OR "observational study" OR "prospective cohort" OR "cohort 
study" OR "longitudinal study" OR "retrospective study" OR "non-randomized" 
OR review OR smoking 
 
 
CINAHL: 
1981 to Present. 
Citations: 2 
Limits: Research article, Human, Exclude MEDLINE records. 
 
Concept 1: (HIV OR "Acquired Immunodeficiency Syndrome")  
 
AND  
 
Concept 2 part 1: (Overweight OR BMI OR "body mass" OR "Waist 
Circumference" OR "weight gain" OR obesity OR obese OR "abdominal fat" OR 
adiposity OR "body fat")  
OR 
Concept 2 part 2 (in article title): anthropometric 
 
AND  
 
Concept 3: (HAART OR ART OR Antiretroviral* OR "Anti-retroviral" OR 
"Anti-retrovirals")  
 
AND  
 
Concept 4 part 1: ("quasi-experimental" OR RCT OR "clinical trial" OR 
random*) 
OR 
Concept 4 part 2: (clinical AND trial) 
 
NOT  
 
Concept 5 part 1: (pregnan* OR wasting OR "weight loss" OR Lipodystroph* OR 
fever OR hepatitis OR carcinogen* OR neoplasm* OR cancer OR cancers OR 
"chronic liver disease" OR "liver fibrosis" OR "fatty liver disease" OR 
atherosclerosis OR "urinary metabolites" OR "urinary abnormalities" OR "renal 
impairment" OR "renal dysfunction"  OR "bone mineral density" OR "skeletal 
muscle toxicity" OR "muscular dystrophy" OR "skeletal muscle disease" OR 
anemia OR tuberculosis OR "neurological disorder" OR "neurocognitive 
impairment" OR "lung disease" OR "alveolar disease" OR "genetic disease" OR 
"genetic abnormalities" OR biomarkers OR markers) 
OR  
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Concept 5 part 2 (in article title): rat OR rats OR mice OR mouse OR dog OR 
dogs OR cats OR "cross-sectional study" OR "case report" OR comment OR 
editorial OR letter OR "case control" OR "case study" OR "case series" OR 
"follow-up study" OR "observational study" OR "prospective cohort" OR "cohort 
study" OR "longitudinal study" OR "retrospective study" OR "non-randomized" 
OR review OR smoking OR dyslipidemi* OR dyslipidaemi* OR 
hypertriglyceridaemi* 
 
Revised search: 0 studies after removing the original. 
 
Concept 1: (HIV OR "Acquired Immunodeficiency Syndrome")  
 
AND  
Concept 2 part 1: (Overweight OR BMI OR "body mass" OR "Waist 
Circumference" OR "weight gain" OR obesity OR obese OR "abdominal fat" OR 
adiposity OR "body fat" OR lipohypertrophy)  
 
OR 
Concept 2 part 2 (in article title): anthropometric 
 
AND  
Concept 3: (HAART OR ART OR Antiretroviral* OR "Anti-retroviral" OR 
"Anti-retrovirals" OR NNRTI OR "protease inhibitor" OR PI)  
 
AND  
Concept 4 part 1: ("quasi-experimental" OR RCT OR "clinical trial" OR 
random*) 
OR 
Concept 4 part 2: (clinical AND trial) 
 
NOT  
Concept 5 part 1: (pregnan* OR wasting OR "weight loss" OR fever OR hepatitis 
OR carcinogen* OR neoplasm* OR cancer OR cancers OR "chronic liver 
disease" OR "liver fibrosis" OR "fatty liver disease" OR atherosclerosis OR 
"urinary metabolites" OR "urinary abnormalities" OR "renal impairment" OR 
"renal dysfunction"  OR "bone mineral density" OR "skeletal muscle toxicity" OR 
"muscular dystrophy" OR "skeletal muscle disease" OR anemia OR tuberculosis 
OR "neurological disorder" OR "neurocognitive impairment" OR "lung disease" 
OR "alveolar disease" OR "genetic disease" OR "genetic abnormalities" OR 
biomarkers OR markers) 
OR  
Concept 5 part 2 (in article title): rat OR rats OR mice OR mouse OR dog OR dogs OR 
cats OR "cross-sectional study" OR "case report" OR comment OR editorial OR letter 
OR "case control" OR "case study" OR "case series" OR "follow-up study" OR 
"observational study" OR "prospective cohort" OR "cohort study" OR "longitudinal 
study" OR "retrospective study" OR "non-randomized" OR review OR smoking  
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PsycINFO 
 
1872 to Present 
Citations: 4 
Limits: Human 
 
Concept 1: (HIV OR "Acquired Immunodeficiency Syndrome")  
 
AND  
Concept 2 part 1: (Overweight OR BMI OR "body mass" OR "Waist 
Circumference" OR "weight gain" OR obesity OR obese OR "abdominal fat" OR 
adiposity OR "body fat")  
OR 
Concept 2 part 2 (in article title): anthropometric 
 
AND  
Concept 3: (HAART OR ART OR Antiretroviral* OR "Anti-retroviral" OR 
"Anti-retrovirals")  
 
AND  
Concept 4 part 1: ("quasi-experimental" OR RCT OR "clinical trial" OR 
random*) 
OR 
Concept 4 part 2: (clinical AND trial) 
 
NOT  
Concept 5 part 1: (pregnan* OR wasting OR "weight loss" OR Lipodystroph* OR 
fever OR hepatitis OR carcinogen* OR neoplasm* OR cancer OR cancers OR 
"chronic liver disease" OR "liver fibrosis" OR "fatty liver disease" OR 
atherosclerosis OR "urinary metabolites" OR "urinary abnormalities" OR "renal 
impairment" OR "renal dysfunction"  OR "bone mineral density" OR "skeletal 
muscle toxicity" OR "muscular dystrophy" OR "skeletal muscle disease" OR 
anemia OR tuberculosis OR "neurological disorder" OR "neurocognitive 
impairment" OR "lung disease" OR "alveolar disease" OR "genetic disease" OR 
"genetic abnormalities" OR biomarkers OR markers) 
OR  
Concept 5 part 2 (in article title): rat OR rats OR mice OR mouse OR dog OR 
dogs OR cats OR "cross-sectional study" OR "case report" OR comment OR 
editorial OR letter OR "case control" OR "case study" OR "case series" OR 
"follow-up study" OR "observational study" OR "prospective cohort" OR "cohort 
study" OR "longitudinal study" OR "retrospective study" OR "non-randomized" 
OR review OR smoking OR dyslipidemi* OR dyslipidaemi* OR 
hypertriglyceridaemi* 
 
 
Revised search: 0 after removing the original studies. 
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Concept 1: (HIV OR "Acquired Immunodeficiency Syndrome")  
 
AND  
Concept 2 part 1: (Overweight OR BMI OR "body mass" OR "Waist 
Circumference" OR "weight gain" OR obesity OR obese OR "abdominal fat" OR 
adiposity OR "body fat" OR lipohypertrophy)  
OR 
Concept 2 part 2 (in article title): anthropometric 
 
AND  
Concept 3: (HAART OR ART OR Antiretroviral* OR "Anti-retroviral" OR 
"Anti-retrovirals" OR NNRTI OR "protease inhibitor" OR PI)  
 
AND  
Concept 4 part 1: ("quasi-experimental" OR RCT OR "clinical trial" OR 
random*) 
OR 
Concept 4 part 2: (clinical AND trial) 
 
NOT  
 
Concept 5 part 1: (pregnan* OR wasting OR "weight loss" OR fever OR hepatitis 
OR carcinogen* OR neoplasm* OR cancer OR cancers OR "chronic liver 
disease" OR "liver fibrosis" OR "fatty liver disease" OR atherosclerosis OR 
"urinary metabolites" OR "urinary abnormalities" OR "renal impairment" OR 
"renal dysfunction"  OR "bone mineral density" OR "skeletal muscle toxicity" OR 
"muscular dystrophy" OR "skeletal muscle disease" OR anemia OR tuberculosis 
OR "neurological disorder" OR "neurocognitive impairment" OR "lung disease" 
OR "alveolar disease" OR "genetic disease" OR "genetic abnormalities" OR 
biomarkers OR markers) 
OR  
Concept 5 part 2 (in article title): rat OR rats OR mice OR mouse OR dog OR dogs OR 
cats OR "cross-sectional study" OR "case report" OR comment OR editorial OR letter 
OR "case control" OR "case study" OR "case series" OR "follow-up study" OR 
"observational study" OR "prospective cohort" OR "cohort study" OR "longitudinal 
study" OR "retrospective study" OR "non-randomized" OR review OR smoking  
 
Cochrane Library: 2 studies. 
Current information only. 
Concept 1: (HIV OR "Acquired Immunodeficiency Syndrome")  
 
AND  
Concept 2: (Overweight OR BMI OR "body mass" OR "Waist Circumference" 
OR "weight gain" OR obesity OR obese OR "abdominal fat" OR adiposity OR 
"body fat" OR anthropometric)  
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AND  
Concept 3: (HAART OR ART OR Antiretroviral* OR "Anti-retroviral" OR 
"Anti-retrovirals")  
 
NOT  
 
Concept 4: (pregnan* OR wasting OR "weight loss" OR Lipodystroph* OR fever 
OR hepatitis OR carcinogen* OR neoplasm* OR cancer OR cancers OR "chronic 
liver disease" OR "liver fibrosis" OR "fatty liver disease" OR atherosclerosis OR 
"urinary metabolites" OR "urinary abnormalities" OR "renal impairment" OR 
"renal dysfunction"  OR "bone mineral density" OR "skeletal muscle toxicity" OR 
"muscular dystrophy" OR "skeletal muscle disease" OR anemia OR tuberculosis 
OR "neurological disorder" OR "neurocognitive impairment" OR "lung disease" 
OR "alveolar disease" OR "genetic disease" OR "genetic abnormalities" OR 
biomarkers OR markers) 
 
 
Revised search: 0 studies after removing the original studies. 
 
Concept 1: (HIV OR "Acquired Immunodeficiency Syndrome")  
 
AND  
Concept 2: (Overweight OR BMI OR "body mass" OR "Waist Circumference" 
OR "weight gain" OR obesity OR obese OR "abdominal fat" OR adiposity OR 
"body fat" OR anthropometric OR lipohypertrophy)  
 
 
AND  
Concept 3: (HAART OR ART OR Antiretroviral* OR "Anti-retroviral" OR 
"Anti-retrovirals" OR NNRTI OR PI OR "protease inhibitor")  
 
 
NOT  
Concept 4: (pregnan* OR wasting OR "weight loss" OR fever OR hepatitis OR 
carcinogen* OR neoplasm* OR cancer OR cancers OR "chronic liver disease" 
OR "liver fibrosis" OR "fatty liver disease" OR atherosclerosis OR "urinary 
metabolites" OR "urinary abnormalities" OR "renal impairment" OR "renal 
dysfunction"  OR "bone mineral density" OR "skeletal muscle toxicity" OR 
"muscular dystrophy" OR "skeletal muscle disease" OR anemia OR tuberculosis 
OR "neurological disorder" OR "neurocognitive impairment" OR "lung disease" 
OR "alveolar disease" OR "genetic disease" OR "genetic abnormalities" OR 
biomarkers OR markers) 
 
Appendix 2: Data Extraction Coding Form 
 
65 
 
 
 
 
EFFECTS OF HIV-MEDICINES AMONG HIV POSITIVE PATIES ON BODY 
HABITUS CHANGE 
A MULTILEVEL META-ANALYSIS 
Developed August 30, 2015 
Code ID: Nusrat=1, Ben=2, Dr. Huedo-medina=4 
Study Information: 
Study_ID: _________ (ID number 001, last name of First Author, Year of Publication without gaps) 
Pub_YR: _________ (Publication Year) 
Data_Coll_Yr: _________ (Year of data collection) 
Lang: _________ (Language of report) 
Journal: _________________________________________________________________________________ 
Impact_Scr: _________ (Impact score of the journal; use ISI Web of Knowledge journal citation reports) 
Fund_Srce: _________ (Funding Source) 0 = No funding   1 = Government     2 = Academic/University  
  3 = Private   4 = Both public and private 
  5 = Other Specific Funding grant: ______________ 
Notes: ___________________________________________________________________________ 
 
Region: _________  0 = Not reported 1= United states 2 = Europe (city: ______)       
        3 = Central America/North America (Mexico, Canada, Caribbean city then specify: ______________) 4 = Africa 
(city: __________) 5 = Asia 6= Australia 7 = Other/Multiple specify 
   (_______________)  
   
City_usa: _______________________ (USA only) Zip_usa: __________________ (Zip-code; US only) 
 
 
 
 
 
 
Notes on sample characteristics relevant to coding  
 
Demographic characteristics: 
 
mean±SD/Median (IQR) for age, gender and ethnicity provided by the study                                                               
Characteristics IN1 IN2 IN3 IN4 
Age of participants 
Mean/median 
Mean_age_IN1 Mean_age_IN2 Mean_age_IN3 Mean_age_IN4 
SD of age SD_age_IN1 SD_age_IN2 SD_age_IN3 SD_age_IN4 
Number/proportio
n of female 
Num/Prop_fem1 Num/Prop_fem2 Num/Prop_fem3 Num/Prop_fem4 
Number/proportio
n of male 
Num/Prop_male
1 
Num/Prop_male2 Num/Prop_male
3 
Num/Prop_male
4 
Ethnicity if 
reported yes=1; 
no=0 
    
Number/ proportion 
of white  
Prop_Whi Number/Proportio
n Black 
 
Prop_Bl  
Number/Proportion 
Latino/Hispanic 
Prop_LH Number/Proportio
n 
Asian 
 
Prop_As  
Number/Proportion 
of Other/Mixed 
Prop_oth    
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Anthropometric measurements in international units at baseline 
 
Characteristic 
 
IN1 
 
IN2 
 
IN3 
 
IN4   
Mean height (cm) Mean_ht_IN1 Mean_htIN2 Mean_htIN3 Mean_htIN4 
SD of height Ht_SD_IN1 Ht_SD_IN2 Ht_SD_IN3 Ht_SD_IN4 
Mean weight (kg) Mean_wt_total Mean_wt_IN1 Mean_wt_IN2 Mean_wt_IN3 
SD of weight Wt_SD_IN1 Wt_SD_IN2 Wt_SD_IN3 Wt_SD_IN4 
Mean BMI (kg/m²) Mean_BMI_total Mean_BMI_IN1 Mean_BMI_IN2 Mean_BMI_IN3 
SD of BMI SD_BMI_IN1 SD_BMI_IN2 SD_BMI_IN3 SD_BMI_IN4 
Mean Waist 
circumference(cm
) 
Mean_WC_IN1 Mean_WC_IN2 Mean_WC_IN3 Mean_WC_IN4 
SD of Waist 
circumference 
SD_WC_IN1 SD_WC_IN2 SD_WC_IN3 SD_WC_IN4 
Mean Waist-hip 
ratio 
Mean_WHR_IN1 Mean_WHR_IN2 Mean_WHR_IN3 Mean_WHR_IN4 
SD of Waist-hip 
ratio 
SD_WHR_IN1 SD__WHR_IN2 SD_WHR_IN3 SD_WHR_IN4 
BMI-Over-Weight BMI_over_IN1 BMI_over_IN2 BMI_over_IN4 BMI_over_IN4 
BMI-Obese-Class1 Obese1_IN1 Obese1_IN2 Obese1_IN3 Obese1_IN4 
BMI-Obese-Class2 Obese2_IN1 Obese2_IN2 Obese2_IN3 Obese2_IN4 
BMI-Obese-Class3 Obese3_IN1 Obese3_IN2 Obese3_IN3 Obese3_IN4 
Mean body fat % 
Mean_bodyfat_IN1 Mean_bodyfat_IN2 Mean_bodyfat_IN3 
Mean_bodyfat_IN
4 
SD of body fat % SD_ bodyfat_IN1 SD_ bodyfat_IN2 SD_ bodyfat_IN3 SD_ bodyfat_IN4 
Method of body fat 
% assessment 
    
Mean Trunk Fat % Trunkfat_IN1 Trunkfat_IN2 Trunkfat_IN3 Trunkfat_IN4 
Mean Limb Fat % Limbfat_IN1 Limbfat_IN2 Limbfat_IN3 Limbfat_IN4 
Mean Sub-
cuteneous Adipose  
Tissue area (cm²) 
Mean_SAT_IN1 Mean_SAT_IN2 Mean_SAT_IN3 Mean_SAT_IN4 
SD Sub-cutaneous 
Adipose  Tissue 
area(cm²) 
SD_SAT_IN1 SD_SAT_IN2 SD_SAT_IN3 SD_SAT_IN4 
Mean Visceral 
Adipose  
Tissue area (cm²) 
Mean_VAT_total Mean_VAT_IN1 Mean_VAT_IN2 Mean_VAT_IN3 
SD Visceral 
Adipose 
Tissue area (cm²) 
SD_VAT_IN1 SD_VAT_IN2 SD_VAT_IN3 SD_VAT_IN4 
Mean Total 
Adipose Tissue 
Area (cm²) 
    
SD Total Adipose 
Tissue 
Area (cm²) 
    
Mean mid arm 
area 
    
SD of mid arm 
area 
    
Mean mid-thigh 
area 
    
SD of mid-thigh 
area 
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Metabolic parameter, HIV risk assessment at baseline (Mean ±SD) 
Characteristic IN1 IN2 IN3 IN4 
Mean fasting Blood 
Glucose (mmol/L) 
Mean_fbloodglu_I
N1 
Mean_fbloodglu_I
N2 
Mean_fbloodglu_IN3 Mean_fbloodglu_IN4 
SD of Fasting Blood 
glucose 
SD_bdglu_IN1 SD_bdglu_IN2 SD_bdglu_IN3 SD_bdglu_IN4 
Mean fasting Insulin 
(mcIU/mL) 
Mean_finsul_IN1 Mean_finsul_IN2 Mean_finsul_IN3 Mean_finsul_IN4 
SD of fasting insulin SD of finsul_IN1 SD of finsul_IN2 SD of finsul_IN3 SD of finsul_IN4 
Mean HgbA1C as % Mean_hgba1c_IN1 Mean_hgba1c_IN2 Mean_hgba1c_IN3 Mean_hgba1c_IN4 
SD of HbA1C SD_hgba1c_IN1 SD_hgba1c_IN2 SD_hgba1c_IN3 SD_hgba1c_IN4 
Mean CD4 cell 
counts 
(cells/mm³) 
Mean_cd4_IN1 Mean_cd4_IN2 Mean_cd4_IN3 Mean_cd4_IN4 
SD of CD4 cell 
counts 
(cells/mm³) 
SD_cd4_IN1 SD_cd4_IN2 SD_cd4_IN3 SD_cd4_IN4 
Mean RNA level 
 (log₁₀ copies/mL) 
Mean_rna_IN1 Mean_rna_IN2 Mean_rna_IN3 Mean_rna_IN4 
SD of RNA level 
 (log₁₀ copies/mL) 
SD_rna_IN1 SD_rna_IN2 SD_rna_IN3 SD_rna_IN4 
 
Lipid profile at baseline (Mean ±SD) 
Characteristic IN1 IN2 IN3 IN4 
Mean Cholesterol 
(mmol/l) 
Mean_chol_IN1 Mean_chol_IN2 Mean_chol_IN3 Mean_chol_IN4 
SD of Cholesterol SD_chol_IN1 SD_chol_IN2 SD_chol_IN3 SD_chol_IN4 
Mean LDL Cholesterol  
(mmol/l) 
Mean_ldl_IN1 Mean_ldl_IN2 Mean_ldl_IN3 Mean_ldl_IN4 
SD of LDL Cholesterol  SD_ ldl_IN1 SD_ ldl_IN2 SD_ ldl_IN3 SD_ ldl_IN4 
Mean HDL Cholesterol 
(mmol/l) 
Mean_hdl_IN1 Mean_hdl_IN1 Mean_hdl_IN2 Mean_hdl_IN3 
SD of HDL Cholesterol SD_hdl_IN1 SD_hdl_IN2 SD_hdl_IN3 SD_hdl_IN4 
Mean Triglyceride 
(mmol/l) 
Mean_tg_IN1 Mean_tg_IN2 Mean_tg_IN3 Mean_tg_IN4 
SD of Triglyceride  SD_ tg_IN1 SD_ tg_IN2 SD_tg_IN3 SD_tg_IN4 
 
Proportion of population on different characteristics 
HIV route of transmission reported: No=0, Yes=1 
                                                                     Intervention/Comparison groups 
 IN1 IN2 IN3 IN4 
Homosexual Homo_IN1 Homo_IN2 Homo_IN3 Homo_IN4 
Heterosexual Hetero_IN1 Hetero_IN2 Hetero_IN3 Hetero_IN4 
Drug users Druguser_IN1 Druguser_IN2 Druguser_IN3 Druguser_IN4 
Blood Transmission Bldtran_IN1 Bldtran_IN2 Bldtran_IN3 Bldtran_IN4 
Other     
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Proportion of population on different characteristics in HIV diagnosis at baseline 
Characteristics  IN1 IN2 IN3 IN4 
Prior to AIDS No=0, 
Yes=1, Unknown=2 
    
AIDS(CDCstage3) AIDS_IN1 AIDS_IN2 AIDS_IN3 AIDS_IN4 
Symptomatic(CDCstage2) Symp_IN1 Symp_IN2 Symp_IN3 Symp_IN4 
Asymptomatic(CDCstage1) Asymp_IN1 Asymp_IN2 Asymp_IN3 Asymp_IN4 
Hepatitis B virus HebB_IN1 HepB_IN2 HepB_IN3 HepB_IN4 
Hepatitis C virus HebC_IN1 HepC_IN2 HepC_IN3 HepC_IN4 
 
 
 
                                                         Intervention /Comparison Condition: 
Number of Participants in intervention and comparison groups in different events 
                                                                     Intervention/Comparison groups 
 IN1 IN2 IN3 IN4 
Participants 
at the beginning  
Part_begIN1 Part_IN2 Part_IN3 Part_IN4 
Participants at the 
end 
Part_end_IN1 Part_end_IN2 Part_end_IN3 Part_end_IN4 
Lost Follow 
Up/missing 
visits 
Lost_fu    
Total number of F/U Num_fu    
Participants 
withdraw 
after randomization/ 
withdraw consent 
Withdraw    
Number of 
participants 
discontinued 
Partc_discont    
Total participant 
adherence in % 
%adherence    
Other reason for 
missing participants 
Other_reasn    
Total number of 
deaths 
Num_death     
Toxicity  
If reported yes=1; 
no=0 
Toxic_rep    
Type of toxicity:  
Specify___________ (ex: 
hepatic toxicity, rash 
due to ART 
medication 
Type_toxic    
Total number of 
participants  having 
toxic effect 
Part_toxic_effect    
 
Intervention and comparison conditions 
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Specify name of intervention conditions (ex: if specific drug of NRTI is given in the study write 
the name in full or short form):______________________________       IN_con_1; IN_con_2; IN_con_3; 
IN_con4; IN_con_5. 
                                                
Intervention settings :___________ IN_setting 
Categories:__________0= not reported                              3= Hospital settings         
                                        1= private office                             4= Multi-center: specify___________ 
                                        2= HIV clinic/ center                    5= Other: specify________________ 
Number of intervention and comparison groups used: __________ IN_com_groups 
Categories:__________1= one control/comparison + one experimental group 
2= one control/comparison + two experimental groups  
3= one control/ comparison + three experimental groups 
4= one control/ comparison + four experimental groups 
Participants assignment in both conditions:___________ Assign_IN                               Assign_com 
Categories: __________0= non-random assignment of individuals. 
1= random assignment of individuals. 
2= not clear/other: specify_____________ 
                                                                         
Composition of both conditions:_________________________ Comp_IN                                  Comp_com 
Categories:__________0= targeted to individual (e.g. randomized as individual) 
                                        1= targeted to groups, other specify:______ 
                                        2= unclear 
Number of participants switch from intervention conditions to comparison /control conditions 
due to drug reaction: 
                                        Numb_switch 
Duration of intervention period: Specify in days, weeks, months. 
Period_IN 
Total number of facilitators in the study:_______ Numb_facil 
Method of delivery: method_del 
Categories: _________          0= delivery by a nurse  
1= delivery by a primary care provider 
2= Delivery by a medical physician 
3= Multiple/ other, specify: __________ 
4= Unclear 
 
Dose in intervention and comparison conditions:____ dose_report 
       0= not reported;                                  1= yes reported 
Amount of dose in intervention and comparison conditions: If unit varies, write unit within 
bracket. 
 IN1_dose IN2_dose IN3_dose IN4_dose 
 
Length of follow up write specifically in days, weeks, months and years. 
Length of follow up in 
different conditions 
IN1_fu IN2_fu IN3_fu IN4_fu 
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Risk Characteristics 
Characteristic 
 
IN1 
 
IN2 
 
IN3 
 
IN4 
Diabetes 
reported (1= 
yes, 0=no)  
If unreported == 
“.” 
diab_report    
Diabetes in 
proportions 
Diab_IN1 Prop_Diab_IN2 Prop_Diab_IN3 Prop_Diab_IN4 
BP reported 
(1=yes, 0=no) 
bp_report    
Proportion 
having High 
blood pressure 
BP_IN1 Prop_BP_IN2 Prop_BP_IN3 Prop_BP_IN4 
LIFESTYLE VARIABLES  
Smokers/smoke
rs (≤6 months) 
(0=no, 1=yes; if 
missing = “.”) 
Smoking_report    
Proportion of 
smoker 
PROP_SMOKE_I
N1  
PROP_SMOKE_I
N2 
PROP_SMOKE_I
N3 
PROP_SMOKE_I
N4 
 
 
Notes on risk characteristics relevant to coding _____________________________________________ 
Methodological Quality Control 
MQ1_____ Random assignment 
0 =Violated randomization and/or 
nonequivalence of comparison group was not 
addressed 
1 = Quasi-experimental design; arbitrary 
assignment; sequential; how: 
_____________________ 
2 = Random assignment of groups of 
individuals. What unit: 
________________________________ 
3 = Matching individuals on some variable 
What variable/s: 
______________________________________ 
4 = True randomization (i.e., participants had 
equal chance of receiving intervention) 
 MQ2_____ Quality control             0 = No standardization 
of treatment is specified 
1 = Treatment standardized by manual, 
specific training, content coding, video as 
main intervention strategy, etc 
 MQ3_____ Pretest post-test design (at least one measure 
pre-post)? (0 = No, 1 = Yes) 
 MQ4_____ Follow-up rate (i.e., largest FU rate at any 
delayed post-test, overall)          
2 = 85-100% completed   1 = 70 – 84% 
completed   0 = <70%  
MQ5_____ Follow-up length (i.e., final assessment 
interval) 
MQ10_____  Withdrawal/Drop-outs (**This category 
applies to cases that withdrew after randomization)     
 0 = Not reported or all non-completers 
were excluded from analyses 
1 = Enumerated and/or compared with 
completed cases (e.g., intent-to-treat; 
baseline differences) 
 MQ11_____Attrition (**This category applies to cases 
lost to follow-up after treatment)    0 = Cases lost to 
follow-up are not considered in outcome reporting 
1 = Enumerated and considered in outcome 
reporting (e.g., included in all possible 
analyses, imputed the mean for lost cases, 
compared with non-attrition at baseline) 
 MQ12_____   Independent/Double-blinding 
0 = Follow-up non-blind, unspecified, or 
questionnaire only    
1 = Follow-up assessment completed by 
independent interviewer blind to group 
assgn 
 MQ13_____Analyses 
0 = No inferential statistical analysis; 
inappropriate, or unspecified 
1 = Appropriate statistical analyses of 
group or time points differences (e.g., 
comparing two groups/measures using at 
least a t or F test but did not control for 
other characteristics). Code this category as 
well if they mention that groups were 
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2 = 6 months or longer   1 = > 3 months or < 6 
months   0 = less than 3 months 
 MQ6_____  Anonymity attempted (if face-to-face 
interviews, mark as ‘0’)  
(0 = No/NR, 1 = Yes) 
 MQ7_____ Low reactivity of measure completion (If they 
do not mention, code “.”) 
0 = no, intervention and measurement staff 
same and face-to-face interviews used 
1 = yes, used different personnel for 
intervention and measurement (face-to-face) 
or  measurement technique not highly 
reactive (written rather than oral questions, 
even if given by same person as intervention) 
 MQ8_____ Collateral verification of self-report 
                    0 = No collateral verification, not reported                  
                    1 = At least some collaterals interviewed; if 
known, _________% 
 MQ9_____ Used objective measures (at FUP, not just 
baseline or for inclusion criteria)         
0 = No objective measure used or unspecified 
(i.e., self-report only)         
1 = Objective measures used in more than 
50% of the cases 
comparable but do not report any statistical 
information about them at baseline or they 
do not mention any statistical test they 
used to demonstrate they did it.(i.e. test to 
compare group at FUP) 
2 = Controlled for baseline and/or other 
characteristics in appropriate statistical 
analyses of group differences (e.g., 
compared two groups using at least a t or F 
test) (i.e. test to compare groups at FUP that 
controls for baseline, or no baseline 
differences found through test and thus no 
need to control for post comparison) 
 MQ14_____Pilot testing   0 = None previous pilot 
testing of the intervention.                    
1 = There was a previous pilot testing of the 
intervention. 
 MQ15_____Intervention content matched to sample 
(0 = No/NR, 1 = Yes) 
 MQ16_____Incentives Offered (0 = No, 1 = Yes) 
 MQ17_____Total Methodological Quality Score (out of 
22 pts) 
 
List of HIV drugs: 
NRTI drugs in combination: Specify subtype of NRTI 
NNRTI drugs in combination: Specify subtype NNRTI 
Protease inhibitors: Specify subtype pi 
Combination of HIV medicines: Specify combination subtype comb 
 
 
Study Quality (Cochrane Risk of Bias Table) on following characteristics: 
 
 Low risk of bias =Yes=1, High risk of bias =No=0, If not specific or, unclear=2 
   
1. Random sequence generation 
2. Allocation sequence concealment 
3. Blinding of participants 
4. Blinding of outcome assessment 
5. Incomplete outcome data 
6. Selective reporting 
7. Other bias 
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Appendix 3: Main HIV medicines with subclasses 
 
Main ART Drug Combined subclass Dummy code
Combined (type12) Comb1 ( as they contain LPV/r as combined treatment) 4
Combined (type1+type12) Comb1 ( as they contain LPV/r as combined treatment) 4
Combined HIV medicine type 12+ type 11 Comb1 ( as they contain LPV/r as combined treatment) 4
Combined HIV medicine type 12+ NNRTI type 4 Comb1 ( as they contain LPV/r as combined treatment) 4
NNRTI+PI/r Comb2 (as they contain PI ) 5
NRTI+PI/r Comb2 (as they contain PI ) 5
NNRTI+NRTI Comb3 (as they contain NNRTI with NRTI) 6
NRTI (type 7&4)+ Combined HIV medicine LPVr (Type 14) Comb1 ( as they contain LPV/r as combined treatment) 4
NNRTI (type4)+Combined HIV medicine LPV/r (type 14) Comb1 ( as they contain LPV/r as combined treatment) 4
Combined (type12) Comb1 ( as they contain LPV/r as combined treatment) 4
Combined (type11+type 12) Comb1 ( as they contain LPV/r as combined treatment) 4
PI+NRTI(type 2+type4) Comb2 (as they contain PI ) 5
PI+NRTI(type 2+type5) Comb2 (as they contain PI ) 5
PI (type7)+NRTI(type2+type5) Comb2 (as they contain PI ) 5
NNRTI(Type 2)+Combination HIV medicine TDF/FTC (Type12) Comb3 (as they contain NNRTI type2) 6
NNRTI(Type 2)+Combination HIV medicine ABC/3TC (Type1) Comb3 (as they contain NNRTI type2) 6
PI+Combination HIV medicine TDF/FTC (Type12) Comb2 (as they contain PI ) 5
PI+Combination HIV medicine ABC/3TC (Type1) Comb2 (as they contain PI ) 5
NNRTI(Type 2)+Combination HIV medicine TDF/FTC (Type12) Comb3 (as they contain NNRTI type2) 6
NNRTI(Type 2)+Combination HIV medicine ABC/3TC (Type1) Comb3 (as they contain NNRTI type2) 6
PI+Combination HIV medicine TDF/FTC (Type12) Comb2 (as they contain PI ) 5
PI+Combination HIV medicine ABC/3TC (Type1) Comb2 (as they contain PI ) 5
NRTI (type 5+ Type 1) NRTI 1
PI/NNRTI+NRTI(ABC Type1) Comb2 (as they contain PI ) 5
NRTI (Type5+ Type1 + Type 7)+PI/NNRTI Comb2 (as they contain PI ) 5
NRTI (type2+3)and NNRTI (type2) Comb3 (as they contain NNRTI type2) 6
NRTI (type5&2) and NNRTI (type2) Comb3 (as they contain NNRTI type2) 6
PI PI 3
NNRTI NNRTI 2
PI+NNRTI Comb2 (as they contain PI ) 5
NRTI NRTI 1
NNRTI+PI Comb2 (as they contain PI ) 5
NRTI(Type4&7)+Combination HIV medicine LPV/r(Type14) Comb1 ( as they contain LPV/r as combined treatment) 4
NNRTI(Type 4)+Combination HIV medicine LPV/r(Type14) Comb1 ( as they contain LPV/r as combined treatment) 4  
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Appendix 4: R syntax 
 
Run the Library in R 
Library ("metafor") 
#Overall effect sizes 
#Regimen NRTI on outcome variable WEIGHT: 
model1<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==1),data=HIVdata,method="REML") 
model1 
#Regimen NRTI on outcome variable BMI: 
model2<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==2),data=HIVdata,method="REML") 
model2 
#Regimen NRTI on outcome variable TRUNKFAT: 
model3<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==3),data=HIVdata,method="REML") 
model3 
#Regimen NRTI on outcome variable LIMBFAT: 
model4<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==4),data=HIVdata,method="REML") 
model4 
#Regimen NRTI on outcome variable TOTAL BODY FAT: 
model5<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==5),data=HIVdata,method="REML") 
model5 
#Regimen NRTI on outcome variable CHOLESTEROL: 
model6<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==6),data=HIVdata,method="REML") 
model6 
#Regimen NRTI on outcome variable HDL: 
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model7<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==7),data=HIVdata,method="REML") 
model7 
#Regimen NRTI on outcome variable LDL: 
model8<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==8),data=HIVdata,method="REML") 
mod 
#Regimen NRTI on outcome variable TG: 
model9<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==9),data=HIVdata,method="REML") 
model9 
#Regimen NRTI on outcome variable SAT: 
model10<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==10),data=HIVdata,method="REML") 
model10 
#Regimen NRTI on outcome variable VAT: 
model11<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==11),data=HIVdata,method="REML") 
model11 
#Regimen NRTI on outcome variable TAT: 
model12<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==12),data=HIVdata,method="REML") 
model12 
#Regimen NNRTI on outcome variable WEIGHT: 
###Special note: 
#No studies reported data on WEIGHT, BMI, Trunkfat,Limbfat, Total bodyfat, SAT, 
VAT, TAT.Only provided on HDL, LDL, TG for NNRTI regimen. 
#That is why we got error messages. Only one study reported those outcome variable that 
is why result showing Fixed effects instead of Random effect. 
model13<-
rma(d.ex.,var_d.ex.,subset=(trt==2&Outcome==1),data=HIVdata,method="REML") 
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model13 
#Regimen NNRTI on outcome variable BMI: 
model14<-
rma(d.ex.,var_d.ex.,subset=(trt==2&Outcome==2),data=HIVdata,method="REML") 
model14 
#Regimen NNRTI on outcome variable TRUNKFAT: 
model15<-
rma(d.ex.,var_d.ex.,subset=(trt==2&Outcome==3),data=HIVdata,method="REML") 
model15 
#Regimen NNRTI on outcome variable LIMBFAT: 
model16<-
rma(d.ex.,var_d.ex.,subset=(trt==2&Outcome==4),data=HIVdata,method="REML") 
model16 
 
#Regimen NNRTI on outcome variable TOTAL BODY FAT: 
model17<-
rma(d.ex.,var_d.ex.,subset=(trt==2&Outcome==5),data=HIVdata,method="REML") 
model17 
#Regimen NNRTI on outcome variable CHOLESTEROL: 
model18<-
rma(d.ex.,var_d.ex.,subset=(trt==2&Outcome==6),data=HIVdata,method="REML") 
model18 
#Regimen NNRTI on outcome variable HDL: 
model19<-
rma(d.ex.,var_d.ex.,subset=(trt==2&Outcome==7),data=HIVdata,method="REML") 
model19 
#Regimen NNRTI on outcome variable LDL: 
model20<-
rma(d.ex.,var_d.ex.,subset=(trt==2&Outcome==8),data=HIVdata,method="REML") 
model20 
#Regimen NNRTI on outcome variable TG: 
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model21<-
rma(d.ex.,var_d.ex.,subset=(trt==2&Outcome==9),data=HIVdata,method="REML") 
model21 
#Regimen NNRTI on outcome variable SAT: 
model22<-
rma(d.ex.,var_d.ex.,subset=(trt==2&Outcome==10),data=HIVdata,method="REML") 
model22 
#Regimen NNRTI on outcome variable VAT: 
model23<-
rma(d.ex.,var_d.ex.,subset=(trt==2&Outcome==11),data=HIVdata,method="REML") 
model23 
#Regimen NNRTI on outcome variable TAT: 
model24<-
rma(d.ex.,var_d.ex.,subset=(trt==2&Outcome==12),data=HIVdata,method="REML") 
model24 
#Regimen PI on outcome variable WEIGHT: 
model25<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==1),data=HIVdata,method="REML") 
model25 
 
#Regimen PI on outcome variable BMI: 
No data on BMI for PI regimen. that is why we got error message. 
model26<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==2),data=HIVdata,method="REML") 
model26 
#Regimen PI on outcome variable TRUNKFAT: 
model27<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==3),data=HIVdata,method="REML") 
model27 
#Regimen PI on outcome variable LIMBFAT: 
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model28<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==4),data=HIVdata,method="REML") 
model28 
#Regimen PI on outcome variable TOTAL BODY FAT: 
No data on TBF. That is why we got error messages. 
model29<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==5),data=HIVdata,method="REML") 
model29 
#Regimen PI on outcome variable CHOLESTEROL: 
model30<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==6),data=HIVdata,method="REML") 
model30 
#Regimen PI on outcome variable HDL: 
model31<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==7),data=HIVdata,method="REML") 
model31 
#Regimen PI on outcome variable LDL: 
model32<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==8),data=HIVdata,method="REML") 
model32 
#Regimen PI on outcome variable TG: 
model33<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==9),data=HIVdata,method="REML") 
model33 
#Regimen PI on outcome variable SAT: 
No data on SAT, VAT and TAT for PI regimen. That is why we got error messages. 
model34<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==10),data=HIVdata,method="REML") 
model34 
 
#Regimen PI on outcome variable VAT: 
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model35<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==11),data=HIVdata,method="REML") 
model35 
#Regimen PI on outcome variable TAT: 
model36<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==12),data=HIVdata,method="REML") 
model36 
#Regimen COMB1 on outcome variable WEIGHT: 
model37<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==1),data=HIVdata,method="REML") 
model37 
#Regimen COMB1 on outcome variable BMI: 
model38<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==2),data=HIVdata,method="REML") 
model38 
#Regimen COMB1 on outcome variable TRUNKFAT: 
model39<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==3),data=HIVdata,method="REML") 
model39 
#Regimen COMB1 on outcome variable LIMBFAT: 
model40<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==4),data=HIVdata,method="REML") 
model40 
#Regimen COMB1 on outcome variable TOTAL BODY FAT: 
model41<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==5),data=HIVdata,method="REML") 
model41 
#Regimen COMB1 on outcome variable CHOLESTEROL: 
model42<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==6),data=HIVdata,method="REML") 
model42 
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#Regimen COMB1 on outcome variable HDL: 
model43<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==7),data=HIVdata,method="REML") 
model43 
 
#Regimen COMB1 on outcome variable LDL: 
model44<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==8),data=HIVdata,method="REML") 
model44 
#Regimen COMB1 on outcome variable TG: 
model45<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==9),data=HIVdata,method="REML") 
model45 
#Regimen COMB1 on outcome variable SAT: 
model46<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==10),data=HIVdata,method="REML") 
model46 
#Regimen COMB1 on outcome variable VAT: 
model47<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==11),data=HIVdata,method="REML") 
model47 
#Regimen COMB1 on outcome variable TAT: 
model48<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==12),data=HIVdata,method="REML") 
model48 
#Regimen COMB2 on outcome variable WEIGHT: 
model49<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==1),data=HIVdata,method="REML") 
model49 
#Regimen COMB2 on outcome variable BMI: 
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model50<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==2),data=HIVdata,method="REML") 
model50 
#Regimen COMB2 on outcome variable TRUNKFAT: 
No data on trunkfat,  
model51<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==3),data=HIVdata,method="REML") 
model51 
#Regimen COMB2 on outcome variable LIMBFAT: 
model53<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==4),data=HIVdata,method="REML") 
model53 
 
#Regimen COMB2 on outcome variable TOTAL BODY FAT: 
model54<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==5),data=HIVdata,method="REML") 
model54 
#Regimen COMB2 on outcome variable CHOLESTEROL: 
model55<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==6),data=HIVdata,method="REML") 
model55 
#Regimen COMB2 on outcome variable HDL: 
model56<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==7),data=HIVdata,method="REML") 
model56 
#Regimen COMB2 on outcome variable LDL: 
model57<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==8),data=HIVdata,method="REML") 
model57 
#Regimen COMB2 on outcome variable TG: 
81 
 
 
 
model58<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==9),data=HIVdata,method="REML") 
model58 
#Regimen COMB2 on outcome variable SAT: 
No data on SAT. 
model59<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==10),data=HIVdata,method="REML") 
model59 
#Regimen COMB2 on outcome variable VAT: 
model60<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==11),data=HIVdata,method="REML") 
model60 
#Regimen COMB2 on outcome variable TAT: 
model61<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==12),data=HIVdata,method="REML") 
model61 
#Regimen COMB3 on outcome variable WEIGHT: 
model62<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==1),data=HIVdata,method="REML") 
model62 
 
#Regimen COMB3 on outcome variable BMI: 
model63<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==2),data=HIVdata,method="REML") 
model63 
#Regimen COMB3 on outcome variable TRUNKFAT: 
model64<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==3),data=HIVdata,method="REML") 
model64 
#Regimen COMB3 on outcome variable LIMBFAT: 
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model65<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==4),data=HIVdata,method="REML") 
model65 
#Regimen COMB3 on outcome variable TOTAL BODY FAT: 
No data on TBF for COMB3 regimen 
model66<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==5),data=HIVdata,method="REML") 
model66 
#Regimen COMB3 on outcome variable CHOLESTEROL: 
model67<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==6),data=HIVdata,method="REML") 
model67 
#Regimen COMB3 on outcome variable HDL: 
model68<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==7),data=HIVdata,method="REML") 
model68 
#Regimen COMB3 on outcome variable LDL: 
model69<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==8),data=HIVdata,method="REML") 
model69 
#Regimen COMB3 on outcome variable TG: 
model70<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==9),data=HIVdata,method="REML") 
model70 
#Regimen COMB3 on outcome variable SAT: No data on SAT. 
model71<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==10),data=HIVdata,method="REML") 
model71 
 
#Regimen COMB3 on outcome variable VAT: 
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model72<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==11),data=HIVdata,method="REML") 
model72 
#Regimen COMB3 on outcome variable TAT: 
No data on TAT. 
model73<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==12),data=HIVdata,method="REML") 
model73 
R code for forest plot 
NRTI for BMI 
model1<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==2),data=HIVdata,method="REML", 
slab= paste(Author, Year, sep="")) 
model1 
par("usr") 
forest(model1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,5,"BMI") 
text(c(-2,2),5,c("NRTI ","Baseline"))  
text(-6,5,"Author Year",pos=4) 
text(5,5,"d[95% CI]",pos=4) 
par(op) 
 
NRTI for cholesterol 
model1<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==6),data=HIVdata,method="REML", 
slab= paste(Author, Year, sep="")) 
par("usr") 
forest(model6,xlim=c(-5,6),xlab="Standardized Mean 
Difference",cex=.9,efac=3,col="dark red",border="black") 
op<-par(cex=0.98, font=2,col="black") 
op<-par(cex=0.98, font=2,col="dark red") 
text (0,13,"Cholesterol") 
text(c(-2,2),13,c("Favors Baseline ","Favors Intervention"))  
text(-5,13,"Author Year",pos=4) 
text(4,13,"d[95% CI]",pos=4) 
par(op) 
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NRTI for HDL 
model1<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==7),data=HIVdata,method="REML", 
slab= paste(Author, Year, sep="")) 
par("usr") 
forest(model14,xlim=c(-5,6),xlab="Standardized Mean 
Difference",cex=.90,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.90, font=2,col="dark red") 
text (0,14,"LDL") 
text(c(-2,2),14,c("NRTI ","Baseline"))  
text(-5,14,"Author Year",pos=4) 
text(4,14,"d[95% CI]",pos=4) 
par(op) 
 
NRTI for LDL 
model1<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==8),data=HIVdata,method="REML", 
slab= paste(Author, Year, sep="")) 
par("usr") 
forest(model14,xlim=c(-5,6),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,15,"LDL") 
text(c(-2,2),15,c("NRTI ","Baseline"))  
text(-5,15,"Author Year",pos=4) 
text(4,15,"d[95% CI]",pos=4) 
par(op) 
 
NRTI for TG 
model1<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==9),data=HIVdata,method="REML", 
slab= paste(Author, Year, sep="")) 
 
par("usr") 
forest(model14,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,15,"TG") 
text(c(-2,2),15,c("NRTI ","Baseline"))  
text(-6,15,"Author Year",pos=4) 
text(7.5,15,"d[95% CI]",pos=4) 
par(op) 
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NRTI for trunk fat 
model1<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==3),data=HIVdata,method="REML", 
slab= paste(Author, Year, sep="")) 
 
par("usr") 
forest(model1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,12,"Trunk Fat") 
text(c(-2,2),12,c("Baseline","NRTI"))  
text(-6,12,"Author Year",pos=4) 
text(5,12,"d[95% CI]",pos=4) 
par(op) 
 
NRTI for limb fat 
model1<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==5),data=HIVdata,method="REML", 
slab= paste(Author, Year, sep="")) 
 
par("usr") 
forest(model1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,10,"Limb Fat") 
text(c(-2,2),10,c("Baseline","NRTI"))  
text(-6,10,"Author Year",pos=4) 
text(5,10,"d[95% CI]",pos=4) 
par(op) 
 
NRTI for Total fat 
model1<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==5),data=HIVdata,method="REML", 
slab= paste(Author, Year, sep="")) 
par("usr") 
forest(model1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,14,"Total Fat") 
text(c(-2,2),14,c("Baseline","NRTI"))  
text(-6,14,"Author Year",pos=4) 
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text(5,14,"d[95% CI]",pos=4) 
par(op) 
 
 
PI for Weight 
pi<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==1),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
pi 
PI for Weight 
par("usr") 
forest(pi,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,3.4,"Weight") 
text(c(-2,2),3.4,c("Baseline","PI"))  
text(-6,3.4,"Author Year",pos=4) 
text(5,3.4,"d[95% CI]",pos=4) 
par(op) 
 
PI for BMI 
pi<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==2),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
pi 
par("usr") 
forest(pi,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,3.4,"BMI") 
text(c(-2,2),3.4,c("Baseline","PI"))  
text(-6,3.4,"Author Year",pos=4) 
text(5,3.4,"d[95% CI]",pos=4) 
par(op) 
 
 
PI for Trunk fat 
pi<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==3),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
pi 
par("usr") 
forest(pi,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
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op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,3.4,"Trunk Fat") 
text(c(-2,2),3.4,c("Baseline","PI"))  
text(-6,3.4,"Author Year",pos=4) 
text(5,3.4,"d[95% CI]",pos=4) 
par(op)par("usr") 
forest(PI,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,3.4,"Trunk Fat") 
text(c(-2,2),3.4,c("NRTI ","Baseline"))  
text(-6,3.4,"Author Year",pos=4) 
text(5,3.4,"d[95% CI]",pos=4) 
par(op) 
 
PI for Limb Fat 
pi<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==4),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
pi 
par("usr") 
forest(pi,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,3.4,"Limb Fat") 
text(c(-2,2),3.4,c("Baseline","PI"))  
text(-6,3.4,"Author Year",pos=4) 
text(5,3.4,"d[95% CI]",pos=4) 
par(op) 
 
PI for Total Fat 
pi<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==5),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
pi 
par("usr") 
forest(pi,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,3.4,"Total Fat") 
text(c(-2,2),3.4,c("Baseline","PI"))  
text(-6,3.4,"Author Year",pos=4) 
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text(5,3.4,"d[95% CI]",pos=4) 
par(op) 
PI for cholesterol  
pi<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==6),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
pi 
par("usr") 
forest(pi,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,3.4,"Cholesterol") 
text(c(-2,2),3.4,c("Baseline","PI"))  
text(-6,3.4,"Author Year",pos=4) 
text(5,3.4,"d[95% CI]",pos=4) 
par(op) 
 
PI for HDL 
pi<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==7),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
pi 
par("usr") 
forest(pi,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,5,"HDL") 
text(c(-2,2),5,c("Baseline","PI"))  
text(-6,5,"Author Year",pos=4) 
text(5,5,"d[95% CI]",pos=4) 
par(op) 
 
PI for LDL 
pi<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==8),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
pi 
par("usr") 
forest(pi,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,5,"LDL") 
text(c(-2,2),5,c("Baseline","PI"))  
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text(-6,5,"Author Year",pos=4) 
text(5,5,"d[95% CI]",pos=4) 
par(op) 
 
 
 
PI for TG 
pi<-
rma(d.ex.,var_d.ex.,subset=(trt==3&Outcome==9),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
pi 
par("usr") 
forest(pi,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,5,"TG") 
text(c(-2,2),5,c("Baseline","PI"))  
text(-6,5,"Author Year",pos=4) 
text(5,5,"d[95% CI]",pos=4) 
par(op) 
 
COMB1 for WEIGHT 
COMB1<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==1),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB1 
par("usr") 
forest(COMB1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,6,"WEIGHT") 
text(c(-2,2),6,c("Baseline","PI"))  
text(-6,6,"Author Year",pos=4) 
text(5,6,"d[95% CI]",pos=4) 
par(op) 
 
COMB1 for BMI 
COMB1<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==2),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB1 
par("usr") 
forest(COMB1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
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op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,3.5,"BMI") 
text(c(-2,2),3.5,c("Baseline","PI"))  
text(-6,3.5,"Author Year",pos=4) 
text(5,3.5,"d[95% CI]",pos=4) 
par(op) 
 
COMB1 for TRUNK FAT 
COMB1<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==3),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB1 
par("usr") 
forest(COMB1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,9.5,"TRUNK FAT") 
text(c(-2,2),9.5,c("Baseline",”COMB ART"))  
text(-6,9.5,"Author Year",pos=4) 
text(5,9.5,"d[95% CI]",pos=4) 
par(op) 
 
COMB1 for LIMB FAT 
COMB1<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==4),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB1 
par("usr") 
forest(COMB1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,6,"LIMB FAT") 
text(c(-2,2),6,c("Baseline","COMB ART"))  
text(-6,6,"Author Year",pos=4) 
text(5,6,"d[95% CI]",pos=4) 
par(op) 
 
COMB1 for TOTAL FAT 
COMB1<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==5),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB1 
par("usr") 
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forest(COMB1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,8,"TOTAL FAT") 
text(c(-2,2),8,c("Baseline","COMB ART"))  
text(-6,8,"Author Year",pos=4) 
text(5,8,"d[95% CI]",pos=4) 
par(op) 
 
COMB1 for CHOLETEROL 
COMB1<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==6),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB1 
par("usr") 
forest(COMB1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,10,"Cholesterol") 
text(c(-2,2),10,c("Baseline","COMB ART"))  
text(-6,10,"Author Year",pos=4) 
text(5,10,"d[95% CI]",pos=4) 
par(op) 
 
 
 
 
COMB1 for HDL 
COMB1<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==7),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB1 
par("usr") 
forest(COMB1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,10,"HDL") 
text(c(-2,2),10,c("Baseline","COMB ART"))  
text(-6,10,"Author Year",pos=4) 
text(5,10,"d[95% CI]",pos=4) 
par(op) 
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COMB1 for LDL 
COMB1<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==8),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB1 
par("usr") 
forest(COMB1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,10,"LDL") 
text(c(-2,2),10,c("Baseline","COMB ART"))  
text(-6,10,"Author Year",pos=4) 
text(5,10,"d[95% CI]",pos=4) 
par(op) 
 
COMB1 for tg 
COMB1<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==9),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB1 
par("usr") 
forest(COMB1,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,10,"TG") 
text(c(-2,2),10,c("Baseline","COMB ART"))  
text(-6,10,"Author Year",pos=4) 
text(5,10,"d[95% CI]",pos=4) 
par(op) 
 
COMB2 for Weight 
COMB2<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==1),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB2 
par("usr") 
forest(COMB2,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,3,"Weight") 
text(c(-2,2),3,c("Baseline","COMB2 ART"))  
text(-6,3,"Author Year",pos=4) 
text(5,3,"d[95% CI]",pos=4) 
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par(op) 
 
COMB2 for BMI 
COMB2<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==2),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB2 
 
par(op)par("usr") 
forest(COMB2,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,7,"BMI93 | P a g e ") 
text(c(-2,2),7,c("Baseline","COMB2 ART"))  
text(-6,7,"Author Year",pos=4) 
text(5,7,"d[95% CI]",pos=4) 
par(op) 
 
COMB2 for Trunk fat 
COMB2<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==3),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB2 
 
par(op)par("usr") 
forest(COMB2,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,8,"TRUNK FAT") 
text(c(-2,2),8,c("Baseline","COMB2 ART"))  
text(-6,8,"Author Year",pos=4) 
text(5,8,"d[95% CI]",pos=4) 
par(op) 
 
 
COMB2 for Limb fat 
COMB2<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==4),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB2 
par(op)par("usr") 
forest(COMB2,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
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op<-par(cex=0.85, font=2,col="dark red") 
text (0,12,"LIMB FAT") 
text(c(-2,2),12,c("Baseline","COMB2 ART"))  
text(-6,12,"Author Year",pos=4) 
text(5,12,"d[95% CI]",pos=4) 
par(op) 
 
COMB2 for Total fat 
COMB2<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==5),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB2 
par(op)par("usr") 
forest(COMB2,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,3.5,"TOTAL FAT") 
text(c(-2,2),3.5,c("Baseline","COMB2 ART"))  
text(-6,3.5,"Author Year",pos=4) 
text(5,3.5,"d[95% CI]",pos=4) 
par(op) 
 
 
COMB2 for cholesterol 
COMB2<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==6),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB2 
 
par(op)par("usr") 
forest(COMB2,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,6.5,"Cholesterol") 
text(c(-2,2),6.5,c("Baseline","COMB2 ART"))  
text(-6,6.5,"Author Year",pos=4) 
text(5,6.5,"d[95% CI]",pos=4) 
par(op) 
 
 
COMB2 for HDL 
COMB2<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==7),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
95 
 
 
 
COMB2 
par(op)par("usr") 
forest(COMB2,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,6,"HDL") 
text(c(-2,2),6,c("Baseline","COMB2 ART"))  
text(-6,6,"Author Year",pos=4) 
text(5,6,"d[95% CI]",pos=4) 
par(op) 
 
COMB2 for LDL 
COMB2<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==8),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB2 
par(op)par("usr") 
forest(COMB2,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,7.5,"LDL") 
text(c(-2,2),7.5,c("Baseline","COMB2 ART"))  
text(-6,7.5,"Author Year",pos=4) 
text(5,7.5,"d[95% CI]",pos=4) 
par(op) 
 
COMB2 for TG 
COMB2<-
rma(d.ex.,var_d.ex.,subset=(trt==5&Outcome==9),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB2 
par(op)par("usr") 
forest(COMB2,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,7.5,"TG") 
text(c(-2,2),7.5,c("Baseline","COMB2 ART"))  
text(-6,7.5,"Author Year",pos=4) 
text(5,7.5,"d[95% CI]",pos=4) 
par(op) 
 
COMB3 for weight 
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COMB3<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==1),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB3 
 
 
par(op)par("usr") 
forest(COMB3,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,3.5,"Weight") 
text(c(-2,2),3.5,c("Baseline","COMB3 ART"))  
text(-6,3.5,"Author Year",pos=4) 
text(5,3.5,"d[95% CI]",pos=4) 
par(op) 
 
Comb 3 for BMI 
COMB3<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==2),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB3 
 
par(op)par("usr") 
forest(COMB3,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,7.5,"BMI") 
text(c(-2,2),7.5,c("Baseline","COMB3 ART"))  
text(-6,7.5,"Author Year",pos=4) 
text(5,7.5,"d[95% CI]",pos=4) 
par(op) 
 
COMB3 for Trunk 
COMB3<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==3),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB3 
par(op)par("usr") 
forest(COMB3,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,3.5,"TRUNK FAT") 
text(c(-2,2),3.5,c("Baseline","COMB3 ART"))  
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text(-6,3.5,"Author Year",pos=4) 
text(5,3.5,"d[95% CI]",pos=4) 
par(op) 
 
COMB3 for LIMB 
COMB3<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==4),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB3 
par(op)par("usr") 
forest(COMB3,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,7.5,"LIMB FAT") 
text(c(-2,2),7.5,c("Baseline","COMB3 ART"))  
text(-6,7.5,"Author Year",pos=4) 
text(5,7.5,"d[95% CI]",pos=4) 
par(op) 
 
COMB3 for Total fat 
COMB3<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==5),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB3 
par("usr") 
forest(COMB3,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,7.5,"Total FAT") 
text(c(-2,2),7.5,c("Baseline","COMB3 ART"))  
text(-6,7.5,"Author Year",pos=4) 
text(5,7.5,"d[95% CI]",pos=4) 
par(op) 
 
COMB3 for Cholesterol 
COMB3<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==6),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB3 
par(op)par("usr") 
forest(COMB3,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
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text (0,4.5,"Cholesterol") 
text(c(-2,2),4.5,c("Baseline","COMB3 ART"))  
text(-6,4.5,"Author Year",pos=4) 
text(5,4.5,"d[95% CI]",pos=4) 
par(op) 
 
 
 
 
COMB3 for HDL 
COMB3<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==7),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB3 
 
 
par(op)par("usr") 
forest(COMB3,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,4.5,"HDL") 
text(c(-2,2),4.5,c("Baseline","COMB3 ART"))  
text(-6,4.5,"Author Year",pos=4) 
text(5,4.5,"d[95% CI]",pos=4) 
par(op) 
 
COMB3 for LDL 
COMB3<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==8),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB3 
 
 
par(op)par("usr") 
forest(COMB3,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,4.5,"LDL") 
text(c(-2,2),4.5,c("Baseline","COMB3 ART"))  
text(-6,4.5,"Author Year",pos=4) 
text(5,4.5,"d[95% CI]",pos=4) 
par(op) 
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COMB3 for TG 
COMB3<-
rma(d.ex.,var_d.ex.,subset=(trt==6&Outcome==9),data=HIVdata,method="REML",sl
ab= paste(Author,Year,sep="")) 
COMB3 
par(op)par("usr") 
forest(COMB3,xlim=c(-6,7),xlab="Standardized Mean 
Difference",cex=.85,efac=2,col="dark red",border="black") 
op<-par(cex=0.85, font=2,col="black") 
op<-par(cex=0.85, font=2,col="dark red") 
text (0,4.5,"TG") 
text(c(-2,2),4.5,c("Baseline","COMB3 ART"))  
text(-6,4.5,"Author Year",pos=4) 
text(5,4.5,"d[95% CI]",pos=4) 
par(op) 
 
R syntax for Meta regression plot 
 
model100<-rma(d.ex.,var_d.ex.,subset=(trt==1 & Outcome==8),mods=Weeks,dat
a=HIVdata, method="REML",slab= paste(Reference, Pub_Year, sep =",")) 
model100pred <- predict(model100,newmods=cbind(seq(0,208,.1))) 
wi=HIVdata$w_d.ex. 
min= min(wi,na.rm=TRUE) 
max= max(wi,na.rm=TRUE) 
size= 1.0 + 6.0 * (wi - min)/(max - min) 
treatldl= subset(HIVdata,trt==1 & Outcome==8)  
 
#Here we have to create the subsample we are working on to just plot the observed 
values of that below 
plot(treatldl$Weeks,treatldl$d.ex.,pch= 21,col="black",bg ="white",cex=size,xlab=
"Number of Weeks",  
 
#Plotting here the observed values of the subsample 
ylab = "LDL Effect Size (d)",xlim=c(0,260),ylim=c(-1,1 )) 
lines(seq(0,208,.1), model100pred$pred,col = "dark red")      
                                 
#Plotting here the regression line and confidence interval of the predictive model 
lines(seq(0,208,.1), model100pred$ci.lb,lty = "dashed", col="dark red") 
lines(seq(0,208,.1), model100pred$ci.ub,lty = "dashed", col="dark red") 
model100<-rma(d.ex.,var_d.ex.,subset=(trt==1 & Outcome==8),mods=Weeks,dat
a=HIVdata,method="REML",slab= paste(Reference,Pub_Year,sep =",")) 
model100pred <- predict(model100, newmods=cbind(seq(0,208,.1))) 
model100 
 
R SYNTAX FOR MODERATOR ANALYSIS Risk of Bias: 
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rsg<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==9),mods=~factor(rand_sequence),da
ta=HIVdata,method="REML") 
rsg 
alloc<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==9),mods=~factor(alloc_conc),data=H
IVdata,method="REML") 
alloc 
blind<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==9),mods=~factor(blinding),data=HI
Vdata,method="REML") 
blind 
outblind<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==9),mods=~factor(outcome_blind),da
ta=HIVdata,method="REML") 
outblind 
incomp<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==9),mods=~factor(incompl_outc_data
),data=HIVdata,method="REML") 
incomp 
selectreport<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==9),mods=~factor(select_report),data
=HIVdata,method="REML") 
selectreport 
otherbias<-
rma(d.ex.,var_d.ex.,subset=(trt==4&Outcome==1),mods=~factor(other_bias),data=
HIVdata,method="REML") 
library("metafor") 
 
#Regimen NRTI on outcome variable WEIGHT: 
model1<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==1),data=HIVdata,method="REML") 
model1 
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Publication Bias 
#pub bias for NRTI and Weight 
#Egger's 
regtest(model1,model="lm",data=HIVdata) 
#Begg's 
ranktest(model1, data=HIVdata) 
#funnel plot 
model1trim=trimfill(model1,data=HIVdata) 
funnel(model1trim) 
 
#Regimen NRTI on outcome variable BMI: 
model2<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==2),data=HIVdata,method="REML") 
model2 
Publication Bias 
#pub bias for NRTI and BMI 
#Egger's 
regtest(model2,model="lm",data=HIVdata) 
#Begg's 
ranktest(model2,data=HIVdata) 
#funnel plot 
model2trim=trimfill(model2,data=HIVdata) 
funnel(model2trim) 
 
#Regimen NRTI on outcome variable TRUNKFAT: 
model3<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==3),data=HIVdata,method="REML") 
model3 
Publication Bias 
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#pub bias for NRTI and BMI 
#Egger's 
regtest(model3,model="lm",data=HIVdata) 
#Begg's 
ranktest(model3,data=HIVdata) 
#funnel plot 
model3trim=trimfill(model3,data=HIVdata) 
funnel(model3trim) 
 
#Regimen NRTI on outcome variable LIMBFAT: 
model4<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==4),data=HIVdata,method="REML") 
model4 
Publication Bias 
#pub bias for NRTI and LIMBFAT 
#Egger's 
regtest(model4,model="lm",data=HIVdata) 
#Begg's 
ranktest(model4,data=HIVdata) 
#funnel plot 
model4trim=trimfill(model4,data=HIVdata) 
funnel(model4trim) 
 
#Regimen NRTI on outcome variable TOTAL BODY FAT: 
model5<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==5),data=HIVdata,method="REML") 
model5 
Publication Bias 
#pub bias for NRTI and TOTAL BODY FAT: 
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#Egger's 
regtest(model5,model="lm",data=HIVdata) 
#Begg's 
ranktest(model5,data=HIVdata) 
#funnel plot 
model5trim=trimfill(model5,data=HIVdata) 
funnel(model5trim) 
#Regimen NRTI on outcome variable CHOLESTEROL: 
model6<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==6),data=HIVdata,method="REML") 
model6 
 
Publication Bias 
#pub bias for NRTI and CHOLESTEROL: 
#Egger's 
regtest(model6,model="lm",data=HIVdata) 
#Begg's 
ranktest(model6,data=HIVdata) 
#funnel plot 
model6trim=trimfill(model6,data=HIVdata) 
funnel(model6trim) 
 
#Regimen NRTI on outcome variable HDL: 
model7<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==7),data=HIVdata,method="REML") 
model7 
Publication Bias 
#pub bias for NRTI and HDL: 
#Egger's 
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regtest(model7,model="lm",data=HIVdata) 
#Begg's 
ranktest(model7,data=HIVdata) 
#funnel plot 
model7trim=trimfill(model7,data=HIVdata) 
funnel(model7trim) 
 
#Regimen NRTI on outcome variable LDL: 
model8<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==8),data=HIVdata,method="REML") 
model8 
#pub bias for NRTI and LDL: 
#Egger's 
regtest(model8,model="lm",data=HIVdata) 
#Begg's 
ranktest(model8,data=HIVdata) 
#funnel plot 
model8trim=trimfill(model8,data=HIVdata) 
funnel(model8trim) 
#Regimen NRTI on outcome variable TG: 
model9<-
rma(d.ex.,var_d.ex.,subset=(trt==1&Outcome==9),data=HIVdata,method="REML") 
model9 
#pub bias for NRTI and TG: 
#Egger's 
regtest(model9,model="lm",data=HIVdata) 
#Begg's 
ranktest(model9,data=HIVdata) 
#funnel plot 
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model9trim=trimfill(model9,data=HIVdata) 
funnel(model9trim) 
 
Multilevel MA R code for outcome HDL 
library ("metafor") 
 
#Calculate total number of participants (Ni) 
HIVhdl$Ni <- unlist(lapply(split(HIVhdl,HIVhdl$study),function(x) rep(sum(x$n1i)+ 
x$n2i[1],each=nrow(x)))) 
 
##Creating the Variance-Covariance Matrix for Multiple Comparisons  
calc.hdlv <- function(x) { 
  hdlv <- matrix(1/x$n2i[1] + outer(x$d.ex., x$d.ex., 
"*")/(2*x$Ni[1]),nrow=nrow(x),ncol=nrow(x)) 
  diag(hdlv) <- x$var_d.ex. 
  hdlv 
} 
hdlV <- lapply(split(HIVhdl,HIVhdl$study), calc.hdlv) 
hdlV <- as.matrix(bdiag(hdlV)) 
hdlV 
 
##Calculating the Weighted Mean ES for HDL Change (Multiple treatments), 
Following Random-Effects Assumptions 
HIVhdl$trt <-as.factor(HIVhdl$trt) (note: code for conversion from integer to 
factor) 
dhdl <- rma.mv(d.ex.,var_d.ex.,hdlV,mods = ~ factor(trt) - 1,random = ~ trt | study, 
struct="UN", data=HIVhdl,method="ML") 
dhdl 
 
 
Multilevel Moderation analysis: 
 
##Special note: We have to run multilevel code for variance co-variance matrix, the
n moderation code each time for all outcome variables. 
 
R code considering week as a moderator for HDL: 
hdl<-rma(d.ex.,var_d.ex.,hdlV,mods = ~ factor(trt) - 1 + HIVhdl$Weeks,data = HIVhdl
,method="ML") 
hdl 
 
 
R code for LDL: 
ldl<-rma(d.ex.,var_d.ex.,ldlV,mods = ~ factor(trt) - 1 + HIVldl$Weeks,data = HIVldl,m
ethod="ML") 
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ldl 
 
 
R code for TG: 
tg<-rma(d.ex.,var_d.ex.,tgV,mods = ~ factor(trt) - 1 + HIVtg$Weeks,data = HIVtg,met
hod="ML") 
tg 
 
R code for Cholesterol: 
chol<-rma(d.ex.,var_d.ex.,cholV,mods = ~ factor(trt) - 1 + HIVchol$Weeks,data = HIV
chol,method="ML") 
chol 
 
R code for Trunk: 
trunk<-rma(d.ex.,var_d.ex.,trunkV,mods = ~ factor(trt) - 1 + HIVtrunk$Weeks,data = 
HIVtrunk,method="ML") 
trunk 
 
R code for Limb: 
limb<-rma(d.ex.,var_d.ex.,limbV,mods = ~ factor(trt) - 1 + HIVlimb$Weeks,data = HI
Vlimb,method="ML") 
limb 
 
 
Methodological quality as a moderator 
 
R code considering week as a moderator for HDL: 
 
hdl<-rma(d.ex.,var_d.ex.,hdlV,mods = ~ factor(trt) - 1 + HIVhdl$mq,data = HIVhdl,m
ethod="ML") 
 hdl 
 
R code for LDL: 
 
ldl<-rma(d.ex.,var_d.ex.,ldlV,mods = ~ factor(trt) - 1 + HIVldl$mq,data = HIVldl,meth
od"ML") 
ldl 
 
R code for TG: 
tg<-rma(d.ex.,var_d.ex.,tgV,mods = ~ factor(trt) - 1 + HIVtg$mq,data = HIVtg,method
="ML") 
tg 
 
R code for Cholesterol: 
chol<-rma(d.ex.,var_d.ex.,cholV,mods = ~ factor(trt) - 1 + HIVchol$mq,data = HIVcho
l,method="ML") 
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chol 
 
 
 
R code for Trunk: 
trunk<-rma(d.ex.,var_d.ex.,trunkV,mods = ~ factor(trt) - 1 + HIVtrunk$mq,data = HI
Vtrunk,method="ML") 
trunk 
 
R code for Limb: 
limb<-rma(d.ex.,var_d.ex.,limbV,mods = ~ factor(trt) - 1 + HIVlimb$mq,data = HIVli
mb,method="ML") 
limb 
 
Publication year as a moderator  
 
R code considering week as a moderator for HDL: 
hdl<-rma(d.ex.,var_d.ex.,hdlV,mods = ~ factor(trt) - 1 + HIVhdl$Pub_Year,data = HIV
hdl,method="ML") 
hdl 
 
R code for LDL: 
ldl<-rma(d.ex.,var_d.ex.,ldlV,mods = ~ factor(trt) - 1 + HIVldl$Pub_Year,data = HIVld
l,method="ML") 
ldl 
 
 
R code for TG: 
tg<-rma(d.ex.,var_d.ex.,tgV,mods = ~ factor(trt) - 1 + HIVtg$Pub_Year,data = HIVtg,m
ethod="ML") 
tg 
 
R code for Cholesterol: 
chol<-rma(d.ex.,var_d.ex.,cholV,mods = ~ factor(trt) - 1 + HIVchol$Pub_Year,data = 
HIVchol,method="ML") 
chol 
 
R code for Trunk: 
trunk<-rma(d.ex.,var_d.ex.,trunkV,mods = ~ factor(trt) - 1 + HIVtrunk$Pub_Year,dat
a = HIVtrunk,method="ML") 
trunk 
 
R code for Limb: 
limb<-rma(d.ex.,var_d.ex.,limbV,mods = ~ factor(trt) - 1 + HIVlimb$Pub_Year,data = 
HIVlimb,method="ML") 
limb 
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Female as a moderator  
 
 
R code for HDL: 
hdl<-rma(d.ex.,var_d.ex.,hdlV,mods = ~ factor(trt) - 1 + HIVhdl$female,data = HIVhd
l,method="ML") 
hdl 
 
R code for LDL: 
ldl<-rma(d.ex.,var_d.ex.,ldlV,mods = ~ factor(trt) - 1 + HIVldl$female,data = HIVldl,m
ethod="ML") 
ldl 
 
 
R code for TG: 
tg<-rma(d.ex.,var_d.ex.,tgV,mods = ~ factor(trt) - 1 + HIVtg$female,data = HIVtg,met
hod="ML") 
tg 
 
R code for Cholesterol: 
chol<-rma(d.ex.,var_d.ex.,cholV,mods = ~ factor(trt) - 1 + HIVchol$female,data = HIV
chol,method="ML") 
chol 
 
R code for Trunk: 
trunk<-rma(d.ex.,var_d.ex.,trunkV,mods = ~ factor(trt) - 1 + HIVtrunk$female,data = 
HIVtrunk,method="ML") 
trunk 
 
 
 
R code for Limb: 
limb<-rma(d.ex.,var_d.ex.,limbV,mods = ~ factor(trt) - 1 + HIVlimb$female,data = HI
Vlimb,method="ML") 
limb 
 
 
Average mean age as a moderator: 
 
R code for HDL: 
hdl<-rma(d.ex.,var_d.ex.,hdlV,mods = ~ factor(trt) - 1 + HIVhdl$avrg_mean_age,data 
= HIVhdl,method="ML") 
hdl 
 
109 
 
 
 
R code for LDL: 
ldl<-rma(d.ex.,var_d.ex.,ldlV,mods = ~ factor(trt) - 1 + HIVldl$avrg_mean_age,data = 
HIVldl,method="ML") 
ldl 
 
 
R code for TG: 
tg<-rma(d.ex.,var_d.ex.,tgV,mods = ~ factor(trt) - 1 + HIVtg$avrg_mean_age,data = H
IVtg,method="ML") 
tg 
 
R code for Cholesterol: 
chol<-rma(d.ex.,var_d.ex.,cholV,mods = ~ factor(trt) - 1 + HIVchol$avrg_mean_age,d
ata = HIVchol,method="ML") 
chol 
 
R code for Trunk: 
trunk<-rma(d.ex.,var_d.ex.,trunkV,mods = ~ factor(trt) - 1 + HIVtrunk$avrg_mean_a
ge,data = HIVtrunk,method="ML") 
trunk 
 
R code for Limb: 
limb<-rma(d.ex.,var_d.ex.,limbV,mods = ~ factor(trt) - 1 + HIVlimb$avrg_mean_age,d
ata = HIVlimb,method="ML") 
limb 
 
